Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial
Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting fir...
Gespeichert in:
| Veröffentlicht in: | The Lancet (British edition) Jg. 387; H. 10024; S. 1163 - 1177 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article |
| Sprache: | Englisch |
| Veröffentlicht: |
England
Elsevier Ltd
19.03.2016
Elsevier Limited Elsevier |
| Schlagworte: | |
| ISSN: | 0140-6736, 1474-547X |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| Abstract | Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone.
Standard of care was hormone therapy for at least 2 years; radiotherapy was encouraged for men with N0M0 disease to November, 2011, then mandated; radiotherapy was optional for men with node-positive non-metastatic (N+M0) disease. Stratified randomisation (via minimisation) allocated men 2:1:1:1 to standard of care only (SOC-only; control), standard of care plus zoledronic acid (SOC + ZA), standard of care plus docetaxel (SOC + Doc), or standard of care with both zoledronic acid and docetaxel (SOC + ZA + Doc). Zoledronic acid (4 mg) was given for six 3-weekly cycles, then 4-weekly until 2 years, and docetaxel (75 mg/m2) for six 3-weekly cycles with prednisolone 10 mg daily. There was no blinding to treatment allocation. The primary outcome measure was overall survival. Pairwise comparisons of research versus control had 90% power at 2·5% one-sided α for hazard ratio (HR) 0·75, requiring roughly 400 control arm deaths. Statistical analyses were undertaken with standard log-rank-type methods for time-to-event data, with hazard ratios (HRs) and 95% CIs derived from adjusted Cox models. This trial is registered at ClinicalTrials.gov (NCT00268476) and ControlledTrials.com (ISRCTN78818544).
2962 men were randomly assigned to four groups between Oct 5, 2005, and March 31, 2013. Median age was 65 years (IQR 60–71). 1817 (61%) men had M+ disease, 448 (15%) had N+/X M0, and 697 (24%) had N0M0. 165 (6%) men were previously treated with local therapy, and median prostate-specific antigen was 65 ng/mL (IQR 23–184). Median follow-up was 43 months (IQR 30–60). There were 415 deaths in the control group (347 [84%] prostate cancer). Median overall survival was 71 months (IQR 32 to not reached) for SOC-only, not reached (32 to not reached) for SOC + ZA (HR 0·94, 95% CI 0·79–1·11; p=0·450), 81 months (41 to not reached) for SOC + Doc (0·78, 0·66–0·93; p=0·006), and 76 months (39 to not reached) for SOC + ZA + Doc (0·82, 0·69–0·97; p=0·022). There was no evidence of heterogeneity in treatment effect (for any of the treatments) across prespecified subsets. Grade 3–5 adverse events were reported for 399 (32%) patients receiving SOC, 197 (32%) receiving SOC + ZA, 288 (52%) receiving SOC + Doc, and 269 (52%) receiving SOC + ZA + Doc.
Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population. Docetaxel chemotherapy, given at the time of long-term hormone therapy initiation, showed evidence of improved survival accompanied by an increase in adverse events. Docetaxel treatment should become part of standard of care for adequately fit men commencing long-term hormone therapy.
Cancer Research UK, Medical Research Council, Novartis, Sanofi-Aventis, Pfizer, Janssen, Astellas, NIHR Clinical Research Network, Swiss Group for Clinical Cancer Research. |
|---|---|
| AbstractList | Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone. Methods Standard of care was hormone therapy for at least 2 years; radiotherapy was encouraged for men with N0M0 disease to November, 2011, then mandated; radiotherapy was optional for men with node-positive non-metastatic (N+M0) disease. Stratified randomisation (via minimisation) allocated men 2:1:1:1 to standard of care only (SOC-only; control), standard of care plus zoledronic acid (SOC + ZA), standard of care plus docetaxel (SOC + Doc), or standard of care with both zoledronic acid and docetaxel (SOC + ZA + Doc). Zoledronic acid (4 mg) was given for six 3-weekly cycles, then 4-weekly until 2 years, and docetaxel (75 mg/m2) for six 3-weekly cycles with prednisolone 10 mg daily. There was no blinding to treatment allocation. The primary outcome measure was overall survival. Pairwise comparisons of research versus control had 90% power at 2·5% one-sided α for hazard ratio (HR) 0·75, requiring roughly 400 control arm deaths. Statistical analyses were undertaken with standard log-rank-type methods for time-to-event data, with hazard ratios (HRs) and 95% CIs derived from adjusted Cox models. This trial is registered atClinicalTrials.gov(NCT00268476) andControlledTrials.com(ISRCTN78818544). Findings 2962 men were randomly assigned to four groups between Oct 5, 2005, and March 31, 2013. Median age was 65 years (IQR 60-71). 1817 (61%) men had M+ disease, 448 (15%) had N+/X M0, and 697 (24%) had N0M0. 165 (6%) men were previously treated with local therapy, and median prostate-specific antigen was 65 ng/mL (IQR 23-184). Median follow-up was 43 months (IQR 30-60). There were 415 deaths in the control group (347 [84%] prostate cancer). Median overall survival was 71 months (IQR 32 to not reached) for SOC-only, not reached (32 to not reached) for SOC + ZA (HR 0·94, 95% CI 0·79-1·11; p=0·450), 81 months (41 to not reached) for SOC + Doc (0·78, 0·66-0·93; p=0·006), and 76 months (39 to not reached) for SOC + ZA + Doc (0·82, 0·69-0·97; p=0·022). There was no evidence of heterogeneity in treatment effect (for any of the treatments) across prespecified subsets. Grade 3-5 adverse events were reported for 399 (32%) patients receiving SOC, 197 (32%) receiving SOC + ZA, 288 (52%) receiving SOC + Doc, and 269 (52%) receiving SOC + ZA + Doc. Interpretation Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population. Docetaxel chemotherapy, given at the time of long-term hormone therapy initiation, showed evidence of improved survival accompanied by an increase in adverse events. Docetaxel treatment should become part of standard of care for adequately fit men commencing long-term hormone therapy. Funding Cancer Research UK, Medical Research Council, Novartis, Sanofi-Aventis, Pfizer, Janssen, Astellas, NIHR Clinical Research Network, Swiss Group for Clinical Cancer Research. Summary Background Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone. Methods Standard of care was hormone therapy for at least 2 years; radiotherapy was encouraged for men with N0M0 disease to November, 2011, then mandated; radiotherapy was optional for men with node-positive non-metastatic (N+M0) disease. Stratified randomisation (via minimisation) allocated men 2:1:1:1 to standard of care only (SOC-only; control), standard of care plus zoledronic acid (SOC + ZA), standard of care plus docetaxel (SOC + Doc), or standard of care with both zoledronic acid and docetaxel (SOC + ZA + Doc). Zoledronic acid (4 mg) was given for six 3-weekly cycles, then 4-weekly until 2 years, and docetaxel (75 mg/m2 ) for six 3-weekly cycles with prednisolone 10 mg daily. There was no blinding to treatment allocation. The primary outcome measure was overall survival. Pairwise comparisons of research versus control had 90% power at 2·5% one-sided α for hazard ratio (HR) 0·75, requiring roughly 400 control arm deaths. Statistical analyses were undertaken with standard log-rank-type methods for time-to-event data, with hazard ratios (HRs) and 95% CIs derived from adjusted Cox models. This trial is registered at ClinicalTrials.gov ( NCT00268476 ) and ControlledTrials.com (ISRCTN78818544). Findings 2962 men were randomly assigned to four groups between Oct 5, 2005, and March 31, 2013. Median age was 65 years (IQR 60–71). 1817 (61%) men had M+ disease, 448 (15%) had N+/X M0, and 697 (24%) had N0M0. 165 (6%) men were previously treated with local therapy, and median prostate-specific antigen was 65 ng/mL (IQR 23–184). Median follow-up was 43 months (IQR 30–60). There were 415 deaths in the control group (347 [84%] prostate cancer). Median overall survival was 71 months (IQR 32 to not reached) for SOC-only, not reached (32 to not reached) for SOC + ZA (HR 0·94, 95% CI 0·79–1·11; p=0·450), 81 months (41 to not reached) for SOC + Doc (0·78, 0·66–0·93; p=0·006), and 76 months (39 to not reached) for SOC + ZA + Doc (0·82, 0·69–0·97; p=0·022). There was no evidence of heterogeneity in treatment effect (for any of the treatments) across prespecified subsets. Grade 3–5 adverse events were reported for 399 (32%) patients receiving SOC, 197 (32%) receiving SOC + ZA, 288 (52%) receiving SOC + Doc, and 269 (52%) receiving SOC + ZA + Doc. Interpretation Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population. Docetaxel chemotherapy, given at the time of long-term hormone therapy initiation, showed evidence of improved survival accompanied by an increase in adverse events. Docetaxel treatment should become part of standard of care for adequately fit men commencing long-term hormone therapy. Funding Cancer Research UK, Medical Research Council, Novartis, Sanofi-Aventis, Pfizer, Janssen, Astellas, NIHR Clinical Research Network, Swiss Group for Clinical Cancer Research. Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone. Standard of care was hormone therapy for at least 2 years; radiotherapy was encouraged for men with N0M0 disease to November, 2011, then mandated; radiotherapy was optional for men with node-positive non-metastatic (N+M0) disease. Stratified randomisation (via minimisation) allocated men 2:1:1:1 to standard of care only (SOC-only; control), standard of care plus zoledronic acid (SOC + ZA), standard of care plus docetaxel (SOC + Doc), or standard of care with both zoledronic acid and docetaxel (SOC + ZA + Doc). Zoledronic acid (4 mg) was given for six 3-weekly cycles, then 4-weekly until 2 years, and docetaxel (75 mg/m2) for six 3-weekly cycles with prednisolone 10 mg daily. There was no blinding to treatment allocation. The primary outcome measure was overall survival. Pairwise comparisons of research versus control had 90% power at 2·5% one-sided α for hazard ratio (HR) 0·75, requiring roughly 400 control arm deaths. Statistical analyses were undertaken with standard log-rank-type methods for time-to-event data, with hazard ratios (HRs) and 95% CIs derived from adjusted Cox models. This trial is registered at ClinicalTrials.gov (NCT00268476) and ControlledTrials.com (ISRCTN78818544). 2962 men were randomly assigned to four groups between Oct 5, 2005, and March 31, 2013. Median age was 65 years (IQR 60–71). 1817 (61%) men had M+ disease, 448 (15%) had N+/X M0, and 697 (24%) had N0M0. 165 (6%) men were previously treated with local therapy, and median prostate-specific antigen was 65 ng/mL (IQR 23–184). Median follow-up was 43 months (IQR 30–60). There were 415 deaths in the control group (347 [84%] prostate cancer). Median overall survival was 71 months (IQR 32 to not reached) for SOC-only, not reached (32 to not reached) for SOC + ZA (HR 0·94, 95% CI 0·79–1·11; p=0·450), 81 months (41 to not reached) for SOC + Doc (0·78, 0·66–0·93; p=0·006), and 76 months (39 to not reached) for SOC + ZA + Doc (0·82, 0·69–0·97; p=0·022). There was no evidence of heterogeneity in treatment effect (for any of the treatments) across prespecified subsets. Grade 3–5 adverse events were reported for 399 (32%) patients receiving SOC, 197 (32%) receiving SOC + ZA, 288 (52%) receiving SOC + Doc, and 269 (52%) receiving SOC + ZA + Doc. Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population. Docetaxel chemotherapy, given at the time of long-term hormone therapy initiation, showed evidence of improved survival accompanied by an increase in adverse events. Docetaxel treatment should become part of standard of care for adequately fit men commencing long-term hormone therapy. Cancer Research UK, Medical Research Council, Novartis, Sanofi-Aventis, Pfizer, Janssen, Astellas, NIHR Clinical Research Network, Swiss Group for Clinical Cancer Research. BACKGROUNDLong-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone.METHODSStandard of care was hormone therapy for at least 2 years; radiotherapy was encouraged for men with N0M0 disease to November, 2011, then mandated; radiotherapy was optional for men with node-positive non-metastatic (N+M0) disease. Stratified randomisation (via minimisation) allocated men 2:1:1:1 to standard of care only (SOC-only; control), standard of care plus zoledronic acid (SOC + ZA), standard of care plus docetaxel (SOC + Doc), or standard of care with both zoledronic acid and docetaxel (SOC + ZA + Doc). Zoledronic acid (4 mg) was given for six 3-weekly cycles, then 4-weekly until 2 years, and docetaxel (75 mg/m(2)) for six 3-weekly cycles with prednisolone 10 mg daily. There was no blinding to treatment allocation. The primary outcome measure was overall survival. Pairwise comparisons of research versus control had 90% power at 2·5% one-sided α for hazard ratio (HR) 0·75, requiring roughly 400 control arm deaths. Statistical analyses were undertaken with standard log-rank-type methods for time-to-event data, with hazard ratios (HRs) and 95% CIs derived from adjusted Cox models. This trial is registered at ClinicalTrials.gov (NCT00268476) and ControlledTrials.com (ISRCTN78818544).FINDINGS2962 men were randomly assigned to four groups between Oct 5, 2005, and March 31, 2013. Median age was 65 years (IQR 60-71). 1817 (61%) men had M+ disease, 448 (15%) had N+/X M0, and 697 (24%) had N0M0. 165 (6%) men were previously treated with local therapy, and median prostate-specific antigen was 65 ng/mL (IQR 23-184). Median follow-up was 43 months (IQR 30-60). There were 415 deaths in the control group (347 [84%] prostate cancer). Median overall survival was 71 months (IQR 32 to not reached) for SOC-only, not reached (32 to not reached) for SOC + ZA (HR 0·94, 95% CI 0·79-1·11; p=0·450), 81 months (41 to not reached) for SOC + Doc (0·78, 0·66-0·93; p=0·006), and 76 months (39 to not reached) for SOC + ZA + Doc (0·82, 0·69-0·97; p=0·022). There was no evidence of heterogeneity in treatment effect (for any of the treatments) across prespecified subsets. Grade 3-5 adverse events were reported for 399 (32%) patients receiving SOC, 197 (32%) receiving SOC + ZA, 288 (52%) receiving SOC + Doc, and 269 (52%) receiving SOC + ZA + Doc.INTERPRETATIONZoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population. Docetaxel chemotherapy, given at the time of long-term hormone therapy initiation, showed evidence of improved survival accompanied by an increase in adverse events. Docetaxel treatment should become part of standard of care for adequately fit men commencing long-term hormone therapy.FUNDINGCancer Research UK, Medical Research Council, Novartis, Sanofi-Aventis, Pfizer, Janssen, Astellas, NIHR Clinical Research Network, Swiss Group for Clinical Cancer Research. Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a multiarm, multistage platform design. It recruits men with high-risk, locally advanced, metastatic or recurrent prostate cancer who are starting first-line long-term hormone therapy. We report primary survival results for three research comparisons testing the addition of zoledronic acid, docetaxel, or their combination to standard of care versus standard of care alone. Standard of care was hormone therapy for at least 2 years; radiotherapy was encouraged for men with N0M0 disease to November, 2011, then mandated; radiotherapy was optional for men with node-positive non-metastatic (N+M0) disease. Stratified randomisation (via minimisation) allocated men 2:1:1:1 to standard of care only (SOC-only; control), standard of care plus zoledronic acid (SOC + ZA), standard of care plus docetaxel (SOC + Doc), or standard of care with both zoledronic acid and docetaxel (SOC + ZA + Doc). Zoledronic acid (4 mg) was given for six 3-weekly cycles, then 4-weekly until 2 years, and docetaxel (75 mg/m(2)) for six 3-weekly cycles with prednisolone 10 mg daily. There was no blinding to treatment allocation. The primary outcome measure was overall survival. Pairwise comparisons of research versus control had 90% power at 2·5% one-sided α for hazard ratio (HR) 0·75, requiring roughly 400 control arm deaths. Statistical analyses were undertaken with standard log-rank-type methods for time-to-event data, with hazard ratios (HRs) and 95% CIs derived from adjusted Cox models. This trial is registered at ClinicalTrials.gov (NCT00268476) and ControlledTrials.com (ISRCTN78818544). 2962 men were randomly assigned to four groups between Oct 5, 2005, and March 31, 2013. Median age was 65 years (IQR 60-71). 1817 (61%) men had M+ disease, 448 (15%) had N+/X M0, and 697 (24%) had N0M0. 165 (6%) men were previously treated with local therapy, and median prostate-specific antigen was 65 ng/mL (IQR 23-184). Median follow-up was 43 months (IQR 30-60). There were 415 deaths in the control group (347 [84%] prostate cancer). Median overall survival was 71 months (IQR 32 to not reached) for SOC-only, not reached (32 to not reached) for SOC + ZA (HR 0·94, 95% CI 0·79-1·11; p=0·450), 81 months (41 to not reached) for SOC + Doc (0·78, 0·66-0·93; p=0·006), and 76 months (39 to not reached) for SOC + ZA + Doc (0·82, 0·69-0·97; p=0·022). There was no evidence of heterogeneity in treatment effect (for any of the treatments) across prespecified subsets. Grade 3-5 adverse events were reported for 399 (32%) patients receiving SOC, 197 (32%) receiving SOC + ZA, 288 (52%) receiving SOC + Doc, and 269 (52%) receiving SOC + ZA + Doc. Zoledronic acid showed no evidence of survival improvement and should not be part of standard of care for this population. Docetaxel chemotherapy, given at the time of long-term hormone therapy initiation, showed evidence of improved survival accompanied by an increase in adverse events. Docetaxel treatment should become part of standard of care for adequately fit men commencing long-term hormone therapy. Cancer Research UK, Medical Research Council, Novartis, Sanofi-Aventis, Pfizer, Janssen, Astellas, NIHR Clinical Research Network, Swiss Group for Clinical Cancer Research. |
| Author | Parker, Christopher C Millman, Robin Russell, J Martin Amos, Claire Clarke, Noel W Beesley, Sharon Brock, Susannah Birtle, Alison J Chowdhury, Simon Laing, Robert Srihari, Narayanan Tsang, David Cross, William Cook, Audrey Hetherington, John Srinivasan, Rajaguru James, Nicholas D Protheroe, Andrew Matheson, David Hughes, Robert Tolan, Shaun Gale, Joanna Gibbs, Stephanie Robinson, Angus J Elliott, Tony McKinna, Fiona Alzouebi, Mymoona de Bono, Johann Attard, Gerhardt Sydes, Matthew R O'Sullivan, Joe M Dearnaley, David P Cathomas, Richard McLaren, Duncan B Spears, Melissa R Staffurth, John Parmar, Mahesh K B Jones, Rob J Mason, Malcolm D Ritchie, Alastair W S Graham, John D Chakraborti, Prabir Parikh, Omi Wagstaff, John Thalmann, George Peedell, Clive Sundar, Santhanam |
| AuthorAffiliation | a Warwick Medical School, University of Warwick, Coventry, UK n Department of Oncology, Poole Hospital NHS Foundation Trust and Royal Bournemouth Hospital NHS Foundation Trust, Chur, Switzerland al The South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK e Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK k Department of Oncology, Weston Park Hospital, Sheffield & Doncaster, UK q Department of Medical Oncology, Guy's Hospital, London, UK aa Department of Oncology, Western General Hospital, Edinburgh, UK i Department of Urology, University Hospital, Bern, Switzerland ab Centre for Cancer Research and Cell Biology, Queens University Belfast/Belfast City Hospital, Belfast, UK af Department of Oncology, Sussex Cancer Centre, Brighton, UK p Department of Oncology, Derby Hospitals NHS Foundation Trust, Royal Derby Hospital, Derby, UK y Department of Oncology, Royal Surrey County Hospital, Guildford, UK u Department of Oncology, Queen's Hospital, R |
| AuthorAffiliation_xml | – name: h Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds – name: r Department of Oncology, Cheltenham General Hospital & Hereford County Hospital, UK – name: i Department of Urology, University Hospital, Bern, Switzerland – name: al The South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK – name: l Kent Oncology Centre, Maidstone Hospital, Maidstone, UK – name: c MRC Clinical Trials Unit at UCL, London, UK – name: ac Department of Oncology, East Lancashire Hospitals NHS Trust, East Lancashire, UK – name: p Department of Oncology, Derby Hospitals NHS Foundation Trust, Royal Derby Hospital, Derby, UK – name: ad Department of Oncology & Radiotherapy, South Tees NHS Trust, Middlesbrough, UK – name: m Department of Oncology, Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK – name: o Kantonsspital Graubünden, Chur, Switzerland – name: ah Department of Oncology, Royal Devon & Exeter Hospital, Exeter, UK/Torbay Hospital, Torquay, UK – name: a Warwick Medical School, University of Warwick, Coventry, UK – name: ak Department of Oncology, Southend & Basildon Hospitals, Essex, UK – name: aj Department of Oncology & Radiotherapy, Clatterbridge Cancer Centre, Wirral, UK – name: g Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK – name: f The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK – name: n Department of Oncology, Poole Hospital NHS Foundation Trust and Royal Bournemouth Hospital NHS Foundation Trust, Chur, Switzerland – name: ab Centre for Cancer Research and Cell Biology, Queens University Belfast/Belfast City Hospital, Belfast, UK – name: e Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK – name: y Department of Oncology, Royal Surrey County Hospital, Guildford, UK – name: ag Department of Oncology, Shrewsbury & Telford Hospitals NHS Trust, Shrewsbury, UK – name: s Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK – name: t Oncology and Haematology Clinical Trials Unit, Queen Alexandra Hospital, Portsmouth, UK – name: w Department of Urology, Hull & East Yorkshire Hospitals NHS Trust, Hull, UK – name: d Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK – name: k Department of Oncology, Weston Park Hospital, Sheffield & Doncaster, UK – name: z Department of Oncology, East Sussex Hospitals Trust, East Sussex, UK – name: ae Department of Oncology, Churchill Hospital, Oxford, UK – name: aa Department of Oncology, Western General Hospital, Edinburgh, UK – name: v Beacon Centre, Musgrove Park Hospital, Taunton, UK – name: af Department of Oncology, Sussex Cancer Centre, Brighton, UK – name: j Patient rep, MRC Clinical Trials Unit at UCL, London, UK – name: u Department of Oncology, Queen's Hospital, Romford, UK – name: b University Hospitals Birmingham NHS Foundation Trust, The Medical School, University of Birmingham, Birmingham, UK – name: x Mount Vernon Group, Mount Vernon Hospital, Middlesex, UK – name: q Department of Medical Oncology, Guy's Hospital, London, UK – name: ai Department of Oncology, Nottingham University Hospitals NHS trust, Nottingham, UK |
| Author_xml | – sequence: 1 givenname: Nicholas D surname: James fullname: James, Nicholas D organization: Warwick Medical School, University of Warwick, Coventry, UK – sequence: 2 givenname: Matthew R surname: Sydes fullname: Sydes, Matthew R email: m.sydes@ucl.ac.uk organization: MRC Clinical Trials Unit at UCL, London, UK – sequence: 3 givenname: Noel W surname: Clarke fullname: Clarke, Noel W organization: Department of Urology, The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK – sequence: 4 givenname: Malcolm D surname: Mason fullname: Mason, Malcolm D organization: Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK – sequence: 5 givenname: David P surname: Dearnaley fullname: Dearnaley, David P organization: The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK – sequence: 6 givenname: Melissa R surname: Spears fullname: Spears, Melissa R organization: MRC Clinical Trials Unit at UCL, London, UK – sequence: 7 givenname: Alastair W S surname: Ritchie fullname: Ritchie, Alastair W S organization: MRC Clinical Trials Unit at UCL, London, UK – sequence: 8 givenname: Christopher C surname: Parker fullname: Parker, Christopher C organization: The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK – sequence: 9 givenname: J Martin surname: Russell fullname: Russell, J Martin organization: Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK – sequence: 10 givenname: Gerhardt surname: Attard fullname: Attard, Gerhardt organization: The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK – sequence: 11 givenname: Johann surname: de Bono fullname: de Bono, Johann organization: The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, UK – sequence: 12 givenname: William surname: Cross fullname: Cross, William organization: Department of Urology, Leeds Teaching Hospitals NHS Trust, Leeds – sequence: 13 givenname: Rob J surname: Jones fullname: Jones, Rob J organization: Institute of Cancer Sciences, University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, UK – sequence: 14 givenname: George surname: Thalmann fullname: Thalmann, George organization: Department of Urology, University Hospital, Bern, Switzerland – sequence: 15 givenname: Claire surname: Amos fullname: Amos, Claire organization: MRC Clinical Trials Unit at UCL, London, UK – sequence: 16 givenname: David surname: Matheson fullname: Matheson, David organization: Patient rep, MRC Clinical Trials Unit at UCL, London, UK – sequence: 17 givenname: Robin surname: Millman fullname: Millman, Robin organization: Patient rep, MRC Clinical Trials Unit at UCL, London, UK – sequence: 18 givenname: Mymoona surname: Alzouebi fullname: Alzouebi, Mymoona organization: Department of Oncology, Weston Park Hospital, Sheffield & Doncaster, UK – sequence: 19 givenname: Sharon surname: Beesley fullname: Beesley, Sharon organization: Kent Oncology Centre, Maidstone Hospital, Maidstone, UK – sequence: 20 givenname: Alison J surname: Birtle fullname: Birtle, Alison J organization: Department of Oncology, Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK – sequence: 21 givenname: Susannah surname: Brock fullname: Brock, Susannah organization: Department of Oncology, Poole Hospital NHS Foundation Trust and Royal Bournemouth Hospital NHS Foundation Trust, Chur, Switzerland – sequence: 22 givenname: Richard surname: Cathomas fullname: Cathomas, Richard organization: Kantonsspital Graubünden, Chur, Switzerland – sequence: 23 givenname: Prabir surname: Chakraborti fullname: Chakraborti, Prabir organization: Department of Oncology, Derby Hospitals NHS Foundation Trust, Royal Derby Hospital, Derby, UK – sequence: 24 givenname: Simon surname: Chowdhury fullname: Chowdhury, Simon organization: Department of Medical Oncology, Guy's Hospital, London, UK – sequence: 25 givenname: Audrey surname: Cook fullname: Cook, Audrey organization: Department of Oncology, Cheltenham General Hospital & Hereford County Hospital, UK – sequence: 26 givenname: Tony surname: Elliott fullname: Elliott, Tony organization: Department of Clinical Oncology, The Christie NHS Foundation Trust, Manchester, UK – sequence: 27 givenname: Joanna surname: Gale fullname: Gale, Joanna organization: Oncology and Haematology Clinical Trials Unit, Queen Alexandra Hospital, Portsmouth, UK – sequence: 28 givenname: Stephanie surname: Gibbs fullname: Gibbs, Stephanie organization: Department of Oncology, Queen's Hospital, Romford, UK – sequence: 29 givenname: John D surname: Graham fullname: Graham, John D organization: Beacon Centre, Musgrove Park Hospital, Taunton, UK – sequence: 30 givenname: John surname: Hetherington fullname: Hetherington, John organization: Department of Urology, Hull & East Yorkshire Hospitals NHS Trust, Hull, UK – sequence: 31 givenname: Robert surname: Hughes fullname: Hughes, Robert organization: Mount Vernon Group, Mount Vernon Hospital, Middlesex, UK – sequence: 32 givenname: Robert surname: Laing fullname: Laing, Robert organization: Department of Oncology, Royal Surrey County Hospital, Guildford, UK – sequence: 33 givenname: Fiona surname: McKinna fullname: McKinna, Fiona organization: Department of Oncology, East Sussex Hospitals Trust, East Sussex, UK – sequence: 34 givenname: Duncan B surname: McLaren fullname: McLaren, Duncan B organization: Department of Oncology, Western General Hospital, Edinburgh, UK – sequence: 35 givenname: Joe M surname: O'Sullivan fullname: O'Sullivan, Joe M organization: Centre for Cancer Research and Cell Biology, Queens University Belfast/Belfast City Hospital, Belfast, UK – sequence: 36 givenname: Omi surname: Parikh fullname: Parikh, Omi organization: Department of Oncology, East Lancashire Hospitals NHS Trust, East Lancashire, UK – sequence: 37 givenname: Clive surname: Peedell fullname: Peedell, Clive organization: Department of Oncology & Radiotherapy, South Tees NHS Trust, Middlesbrough, UK – sequence: 38 givenname: Andrew surname: Protheroe fullname: Protheroe, Andrew organization: Department of Oncology, Churchill Hospital, Oxford, UK – sequence: 39 givenname: Angus J surname: Robinson fullname: Robinson, Angus J organization: Department of Oncology, Sussex Cancer Centre, Brighton, UK – sequence: 40 givenname: Narayanan surname: Srihari fullname: Srihari, Narayanan organization: Department of Oncology, Shrewsbury & Telford Hospitals NHS Trust, Shrewsbury, UK – sequence: 41 givenname: Rajaguru surname: Srinivasan fullname: Srinivasan, Rajaguru organization: Department of Oncology, Royal Devon & Exeter Hospital, Exeter, UK/Torbay Hospital, Torquay, UK – sequence: 42 givenname: John surname: Staffurth fullname: Staffurth, John organization: Cardiff University School of Medicine, Velindre Hospital, Cardiff, UK – sequence: 43 givenname: Santhanam surname: Sundar fullname: Sundar, Santhanam organization: Department of Oncology, Nottingham University Hospitals NHS trust, Nottingham, UK – sequence: 44 givenname: Shaun surname: Tolan fullname: Tolan, Shaun organization: Department of Oncology & Radiotherapy, Clatterbridge Cancer Centre, Wirral, UK – sequence: 45 givenname: David surname: Tsang fullname: Tsang, David organization: Department of Oncology, Southend & Basildon Hospitals, Essex, UK – sequence: 46 givenname: John surname: Wagstaff fullname: Wagstaff, John organization: The South West Wales Cancer Institute and Swansea University College of Medicine, Swansea, UK – sequence: 47 givenname: Mahesh K B surname: Parmar fullname: Parmar, Mahesh K B organization: MRC Clinical Trials Unit at UCL, London, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26719232$$D View this record in MEDLINE/PubMed |
| BookMark | eNqNkl1rFDEYhQep2G31JygBb7bQ0WQmmQ_FSqnrB1QUWsG7kEne2U2bSdYku1h_pz_ITLetWpB6NUNy3icnOWcn27LOQpY9JvgZwaR6foIJxXlVl9WUsD1McFnn7F42IbSmOaP1161sciPZznZCOMMY0wqzB9l2UdWkLcpikv08VEpH7SxyPVJOQhTfweyjH86A8s5qiYTUah85jzoXFyg61GsfYm60BWScnecR_IAWzg_JIYoL8GJ5gbRFS-9CFBGQFFaCR9OT08OPn2dvZnsvUFj5tV4LgzyElYkB9d4NSFgklFhGvYZ9NKR1Lfxw9ZdQ87S6NCL26SzkhVVu0AEUks5G70xyjKLXwjzM7vfCBHh09d3NvrydnR69z48_vftwdHicy6qmMQdWKCC0Vx2Drio6Kru-F11di7Jt2q4tW9L2RMia0LYgDFcAZYNLJqFRTVeocjc72HCXq24AJSHZEIYvvR6Ev-BOaP73jtULPndrTpuURckSYHoF8O7bCkLk6UISjBEW3CpwUtc1bRhtmyR9ekt65lbepuuNKkYwJbRKqid_Orqxch14ErzcCGQKJ3joudQpIz2-oNCGE8zHevHLevGxO5wwflkvPvplt6avD7hr7vVmDlIaaw2eB6khlUJpDzJy5fSdhINbBJkKqKUw53AB4fdb8FBwvIGMjBTbSBgBr_4N-A8DvwAWaBRG |
| CODEN | LANCAO |
| CitedBy_id | crossref_primary_10_1016_j_clon_2017_01_007 crossref_primary_10_1177_15579883221115593 crossref_primary_10_1016_j_critrevonc_2020_103185 crossref_primary_10_1016_j_mayocp_2019_09_030 crossref_primary_10_3390_jcm13206221 crossref_primary_10_3390_cancers14010166 crossref_primary_10_1007_s00432_023_04658_6 crossref_primary_10_1158_1078_0432_CCR_17_1034 crossref_primary_10_1016_j_euo_2019_01_004 crossref_primary_10_1007_s00120_018_0680_9 crossref_primary_10_1002_cncr_31285 crossref_primary_10_1002_pros_23762 crossref_primary_10_1038_s41391_018_0055_8 crossref_primary_10_1200_JCO_2017_75_3921 crossref_primary_10_1210_js_2018_00052 crossref_primary_10_1007_s00345_019_02704_y crossref_primary_10_1186_s12885_024_13147_z crossref_primary_10_1080_17460441_2021_1829588 crossref_primary_10_1016_j_euo_2024_04_001 crossref_primary_10_1016_j_currproblcancer_2018_05_007 crossref_primary_10_1016_j_euf_2016_11_017 crossref_primary_10_1093_jjco_hyy129 crossref_primary_10_1016_j_cbi_2021_109477 crossref_primary_10_1016_j_critrevonc_2025_104698 crossref_primary_10_1200_JCO_24_01907 crossref_primary_10_1111_bju_14091 crossref_primary_10_1001_jama_2025_0228 crossref_primary_10_1016_j_acuro_2022_12_004 crossref_primary_10_1016_j_ctro_2022_09_003 crossref_primary_10_1016_j_prnil_2017_01_002 crossref_primary_10_1016_j_yao_2023_12_006 crossref_primary_10_1016_j_ejca_2018_01_001 crossref_primary_10_1172_JCI132184 crossref_primary_10_1016_j_clgc_2019_08_004 crossref_primary_10_4103_ijmpo_ijmpo_259_17 crossref_primary_10_1016_j_euf_2019_01_018 crossref_primary_10_1002_pros_24885 crossref_primary_10_1007_s40336_018_0274_y crossref_primary_10_1016_j_acuroe_2024_06_005 crossref_primary_10_1016_j_euo_2024_05_016 crossref_primary_10_1002_pros_24404 crossref_primary_10_1007_s11255_025_04389_2 crossref_primary_10_1038_s41391_020_00278_0 crossref_primary_10_1002_pros_24406 crossref_primary_10_1016_j_ctrv_2025_102941 crossref_primary_10_1016_j_ajpath_2024_07_019 crossref_primary_10_1007_s00761_017_0284_9 crossref_primary_10_1080_20009666_2020_1811069 crossref_primary_10_1016_j_euo_2018_06_004 crossref_primary_10_1016_j_urolonc_2017_12_009 crossref_primary_10_1007_s00259_023_06165_9 crossref_primary_10_3389_fpubh_2025_1574780 crossref_primary_10_1016_j_eururo_2016_08_002 crossref_primary_10_1111_ijcp_13874 crossref_primary_10_1177_1073274819870549 crossref_primary_10_1002_pros_23309 crossref_primary_10_1158_1078_0432_CCR_21_0024 crossref_primary_10_1002_rcr2_347 crossref_primary_10_1016_j_euf_2019_01_015 crossref_primary_10_1016_j_euf_2019_01_016 crossref_primary_10_1080_14737159_2017_1345627 crossref_primary_10_4103_UCCI_UCCI_3_24 crossref_primary_10_1002_pros_24636 crossref_primary_10_1016_j_eururo_2019_06_014 crossref_primary_10_1016_S1470_2045_22_00507_1 crossref_primary_10_1177_03008916221079662 crossref_primary_10_1056_NEJMoa1702900 crossref_primary_10_1111_jcmm_13604 crossref_primary_10_1007_s10147_017_1160_8 crossref_primary_10_1186_s13045_020_00978_z crossref_primary_10_1371_journal_pone_0191455 crossref_primary_10_1016_j_eururo_2020_04_063 crossref_primary_10_3390_cancers14071784 crossref_primary_10_1002_cam4_4074 crossref_primary_10_1080_0284186X_2019_1662084 crossref_primary_10_1007_s00280_019_03905_3 crossref_primary_10_1186_s12917_022_03544_6 crossref_primary_10_1016_j_clon_2016_07_004 crossref_primary_10_1016_j_critrevonc_2025_104678 crossref_primary_10_1016_j_urolonc_2023_11_021 crossref_primary_10_1186_s12935_020_01229_4 crossref_primary_10_1200_JCO_19_00799 crossref_primary_10_1016_j_eururo_2017_03_027 crossref_primary_10_1111_imj_15288 crossref_primary_10_1002_sim_9733 crossref_primary_10_1186_s40001_022_00773_1 crossref_primary_10_2217_fon_2017_0270 crossref_primary_10_1038_s41571_019_0167_7 crossref_primary_10_1158_1541_7786_MCR_16_0392 crossref_primary_10_1007_s00120_019_0881_x crossref_primary_10_1002_tcr_202000104 crossref_primary_10_1055_s_0041_1732851 crossref_primary_10_1016_j_clgc_2017_04_013 crossref_primary_10_1016_j_eururo_2017_10_002 crossref_primary_10_2147_OTT_S242921 crossref_primary_10_1016_j_clgc_2017_04_016 crossref_primary_10_1093_annonc_mdx348 crossref_primary_10_1016_j_urology_2017_07_032 crossref_primary_10_1002_cnr2_1790 crossref_primary_10_1038_bjc_2016_251 crossref_primary_10_1200_EDBK_175496 crossref_primary_10_1007_s00761_022_01124_9 crossref_primary_10_1007_s00345_022_04134_9 crossref_primary_10_1038_s41571_019_0254_9 crossref_primary_10_1111_ijcp_13611 crossref_primary_10_1016_j_euros_2020_12_006 crossref_primary_10_1016_S1470_2045_17_30911_7 crossref_primary_10_3389_fonc_2022_1059410 crossref_primary_10_3390_cancers14030815 crossref_primary_10_1097_MOU_0000000000000675 crossref_primary_10_1002_sim_7324 crossref_primary_10_1097_MOU_0000000000000434 crossref_primary_10_1186_s12885_019_5709_y crossref_primary_10_1002_pros_23967 crossref_primary_10_1371_journal_pone_0276081 crossref_primary_10_1016_j_euf_2016_12_008 crossref_primary_10_3390_cancers14082017 crossref_primary_10_1136_bmj_2023_075512 crossref_primary_10_1016_j_euros_2022_09_002 crossref_primary_10_1080_14737140_2016_1243474 crossref_primary_10_1007_s40266_019_00677_6 crossref_primary_10_3390_ijms22137178 crossref_primary_10_1016_j_fpurol_2020_10_002 crossref_primary_10_1016_j_intimp_2024_113404 crossref_primary_10_1200_JCO_19_01863 crossref_primary_10_1016_j_annonc_2025_07_005 crossref_primary_10_1111_bju_15384 crossref_primary_10_1056_NEJMc1803343 crossref_primary_10_1136_bmjopen_2019_034708 crossref_primary_10_1002_cam4_5587 crossref_primary_10_1007_s11136_019_02212_x crossref_primary_10_1097_MOU_0000000000000443 crossref_primary_10_1007_s12325_018_0825_7 crossref_primary_10_1016_j_clon_2019_04_012 crossref_primary_10_1097_MOU_0000000000000444 crossref_primary_10_1111_bju_14050 crossref_primary_10_1016_j_ijrobp_2016_12_006 crossref_primary_10_1097_MOU_0000000000000446 crossref_primary_10_1016_j_euros_2022_09_009 crossref_primary_10_1111_ajco_13578 crossref_primary_10_1002_pros_23733 crossref_primary_10_1016_S0140_6736_21_00950_8 crossref_primary_10_1038_s41391_021_00397_2 crossref_primary_10_1016_j_clgc_2023_03_009 crossref_primary_10_1080_14737140_2021_1843430 crossref_primary_10_1038_s41391_023_00696_w crossref_primary_10_1007_s12032_021_01566_y crossref_primary_10_1038_s41588_018_0086_z crossref_primary_10_1038_s41585_019_0237_8 crossref_primary_10_3390_biom12020309 crossref_primary_10_1007_s12032_021_01520_y crossref_primary_10_1016_j_ctrv_2017_04_008 crossref_primary_10_1016_j_eururo_2017_10_029 crossref_primary_10_1016_j_clon_2020_01_002 crossref_primary_10_1016_j_eururo_2017_10_028 crossref_primary_10_3390_jpm12010008 crossref_primary_10_1007_s11864_020_00798_w crossref_primary_10_3390_ijms26136244 crossref_primary_10_1007_s00259_019_4261_y crossref_primary_10_3390_app122110949 crossref_primary_10_1007_s00120_018_0607_5 crossref_primary_10_1007_s00092_017_1589_0 crossref_primary_10_1038_s41598_020_69424_x crossref_primary_10_1097_CAD_0000000000001419 crossref_primary_10_1007_s00120_021_01704_4 crossref_primary_10_1111_iju_14801 crossref_primary_10_1016_j_eujim_2021_101302 crossref_primary_10_1016_j_clgc_2020_03_017 crossref_primary_10_1007_s13629_017_0196_x crossref_primary_10_1093_annonc_mdx312 crossref_primary_10_3389_fonc_2020_519388 crossref_primary_10_1002_ijc_32509 crossref_primary_10_1016_j_bulcan_2017_06_001 crossref_primary_10_1016_j_euf_2019_02_006 crossref_primary_10_1038_s42003_025_08384_2 crossref_primary_10_1016_S1470_2045_23_00230_9 crossref_primary_10_1177_1352458517729460 crossref_primary_10_1016_j_critrevonc_2017_09_003 crossref_primary_10_1016_j_drup_2021_100761 crossref_primary_10_3390_cancers13163947 crossref_primary_10_1016_j_canlet_2024_217355 crossref_primary_10_1093_oncolo_oyaf095 crossref_primary_10_1016_j_ctarc_2021_100384 crossref_primary_10_1016_j_clinthera_2020_05_010 crossref_primary_10_1073_pnas_1600420113 crossref_primary_10_1002_jbmr_4391 crossref_primary_10_3390_cancers14040864 crossref_primary_10_1016_j_neo_2021_06_013 crossref_primary_10_1038_nrclinonc_2017_160 crossref_primary_10_3389_fonc_2021_627083 crossref_primary_10_1007_s12094_022_03019_y crossref_primary_10_1177_10781552211037322 crossref_primary_10_1038_s41420_022_00951_4 crossref_primary_10_1200_GO_20_00505 crossref_primary_10_1056_NEJMoa1911206 crossref_primary_10_1200_OP_24_00690 crossref_primary_10_2217_fon_2016_0223 crossref_primary_10_2217_fon_2016_0464 crossref_primary_10_1007_s40336_016_0204_9 crossref_primary_10_1016_j_acuro_2024_06_001 crossref_primary_10_1016_j_eururo_2022_08_002 crossref_primary_10_1016_j_ijrobp_2025_01_025 crossref_primary_10_1007_s00120_018_0669_4 crossref_primary_10_1148_radiol_2018171046 crossref_primary_10_4103_iju_IJU_115_20 crossref_primary_10_1007_s11095_019_2706_4 crossref_primary_10_2217_fon_2023_0814 crossref_primary_10_1016_j_ctrv_2016_09_008 crossref_primary_10_1155_2018_1525832 crossref_primary_10_4103_UA_UA_47_20 crossref_primary_10_1111_cas_15718 crossref_primary_10_1080_17512433_2023_2181783 crossref_primary_10_1016_S1470_2045_21_00025_5 crossref_primary_10_1111_iju_13090 crossref_primary_10_1111_bcp_13889 crossref_primary_10_1097_PPO_0000000000000215 crossref_primary_10_3389_fonc_2023_1104242 crossref_primary_10_1200_JCO_2018_78_0031 crossref_primary_10_1001_jamanetworkopen_2023_40787 crossref_primary_10_3390_cancers13163966 crossref_primary_10_1016_j_eururo_2025_06_009 crossref_primary_10_3390_cancers16091643 crossref_primary_10_1002_pros_23378 crossref_primary_10_1056_NEJMoa1903835 crossref_primary_10_1016_j_ejca_2018_03_007 crossref_primary_10_1200_JCO_2016_72_1076 crossref_primary_10_1002_pros_23395 crossref_primary_10_1038_s41388_025_03573_z crossref_primary_10_1016_j_clgc_2019_07_007 crossref_primary_10_1111_bju_14025 crossref_primary_10_1016_j_neo_2021_11_006 crossref_primary_10_3389_fphar_2020_555475 crossref_primary_10_1136_bmj_m115 crossref_primary_10_1188_20_CJON_369_378 crossref_primary_10_1200_JGO_2016_007807 crossref_primary_10_1016_j_mam_2019_100837 crossref_primary_10_1002_pros_24253 crossref_primary_10_1007_s00280_024_04684_2 crossref_primary_10_1016_j_mcna_2017_10_001 crossref_primary_10_1097_SP9_0000000000000009 crossref_primary_10_1038_s41391_020_0261_z crossref_primary_10_1016_j_euo_2024_07_011 crossref_primary_10_1136_bmjmed_2023_000497 crossref_primary_10_1016_j_ejca_2025_115335 crossref_primary_10_1097_JU_0000000000003876 crossref_primary_10_1111_iju_15499 crossref_primary_10_1007_s00345_020_03111_4 crossref_primary_10_1080_17512433_2018_1429265 crossref_primary_10_1007_s00120_017_0459_4 crossref_primary_10_1016_j_clon_2023_10_054 crossref_primary_10_1111_bju_15364 crossref_primary_10_1111_cas_14889 crossref_primary_10_1200_JCO_2016_72_1068 crossref_primary_10_1016_j_ejca_2023_02_018 crossref_primary_10_3389_fonc_2020_567616 crossref_primary_10_4103_iju_iju_402_21 crossref_primary_10_1016_j_landig_2025_100885 crossref_primary_10_1038_nrclinonc_2017_120 crossref_primary_10_1016_j_bone_2020_115735 crossref_primary_10_1007_s12094_017_1783_2 crossref_primary_10_1016_j_clgc_2017_12_012 crossref_primary_10_1016_j_urolonc_2020_05_005 crossref_primary_10_1001_jamanetworkopen_2025_9433 crossref_primary_10_1080_17843286_2021_2001999 crossref_primary_10_1097_PPO_0000000000000429 crossref_primary_10_1016_j_acuroe_2020_10_007 crossref_primary_10_1097_PPO_0000000000000424 crossref_primary_10_2217_fon_2021_0320 crossref_primary_10_1016_j_clon_2017_10_004 crossref_primary_10_1097_PPO_0000000000000423 crossref_primary_10_1001_jamanetworkopen_2020_33787 crossref_primary_10_1055_a_1399_7718 crossref_primary_10_1097_MOU_0000000000001125 crossref_primary_10_1097_PPO_0000000000000432 crossref_primary_10_1007_s10147_019_01577_w crossref_primary_10_1007_s10147_016_1037_2 crossref_primary_10_1177_10732748241274190 crossref_primary_10_3389_fphar_2017_00249 crossref_primary_10_1016_j_clon_2019_12_010 crossref_primary_10_1007_s00280_019_03862_x crossref_primary_10_1080_14737140_2023_2208352 crossref_primary_10_1371_journal_pone_0197606 crossref_primary_10_1038_s41416_020_01105_y crossref_primary_10_1186_s13046_017_0578_1 crossref_primary_10_3390_diagnostics8030062 crossref_primary_10_1080_0284186X_2023_2199940 crossref_primary_10_1159_000507054 crossref_primary_10_1007_s00223_017_0369_x crossref_primary_10_1016_j_yao_2021_02_022 crossref_primary_10_3390_bs13060449 crossref_primary_10_1016_j_ejca_2024_114002 crossref_primary_10_1002_pros_24898 crossref_primary_10_1016_j_acuroe_2022_12_004 crossref_primary_10_1038_s41391_020_00280_6 crossref_primary_10_1016_j_eururo_2019_12_020 crossref_primary_10_3390_biochem3030009 crossref_primary_10_1016_S0140_6736_16_31041_8 crossref_primary_10_2217_fon_2016_0279 crossref_primary_10_1097_JU_0000000000003452 crossref_primary_10_1097_PPO_0000000000000418 crossref_primary_10_1136_bmj_2021_067745 crossref_primary_10_1007_s00066_017_1252_4 crossref_primary_10_1016_j_jfma_2020_06_021 crossref_primary_10_1186_s13063_020_04334_x crossref_primary_10_3389_fonc_2020_587981 crossref_primary_10_1007_s15006_017_9037_3 crossref_primary_10_1016_S1470_2045_23_00063_3 crossref_primary_10_1097_PPO_0000000000000421 crossref_primary_10_1016_j_eururo_2020_06_022 crossref_primary_10_31083_j_fbl2701034 crossref_primary_10_3390_medsci7080085 crossref_primary_10_3390_ijms20092066 crossref_primary_10_1007_s00259_023_06321_1 crossref_primary_10_1016_j_acuro_2024_07_003 crossref_primary_10_1016_j_clgc_2017_12_006 crossref_primary_10_1200_EDBK_279459 crossref_primary_10_1016_j_urolonc_2022_09_010 crossref_primary_10_1038_s41391_022_00560_3 crossref_primary_10_1038_bjc_2017_474 crossref_primary_10_1186_s13014_020_01577_5 crossref_primary_10_1038_s41391_018_0060_y crossref_primary_10_3390_cancers14010147 crossref_primary_10_1007_s00345_018_2448_7 crossref_primary_10_1002_cam4_2003 crossref_primary_10_1111_bju_15553 crossref_primary_10_1016_j_clgc_2021_02_004 crossref_primary_10_3390_cancers15153969 crossref_primary_10_1111_bju_15550 crossref_primary_10_1007_s11934_025_01272_6 crossref_primary_10_1016_j_clgc_2023_12_018 crossref_primary_10_1016_j_euo_2024_06_015 crossref_primary_10_1177_2051415816681238 crossref_primary_10_1371_journal_pone_0275176 crossref_primary_10_1038_s41598_020_80534_4 crossref_primary_10_1016_j_fpurol_2024_07_205 crossref_primary_10_1016_j_fpurol_2024_07_204 crossref_primary_10_1016_j_euf_2017_01_019 crossref_primary_10_1016_j_urology_2016_10_044 crossref_primary_10_18027_2224_5057_2024_018 crossref_primary_10_1111_bju_14239 crossref_primary_10_1016_j_clgc_2017_05_005 crossref_primary_10_1016_j_ejca_2018_11_032 crossref_primary_10_1093_jncics_pkab082 crossref_primary_10_1093_jncics_pkab083 crossref_primary_10_1016_j_ejca_2024_115110 crossref_primary_10_1055_a_1892_4251 crossref_primary_10_1016_j_eururo_2019_11_003 crossref_primary_10_3390_jcm14082565 crossref_primary_10_4137_CMO_S34535 crossref_primary_10_1038_s41391_019_0161_2 crossref_primary_10_1016_j_jmir_2019_05_006 crossref_primary_10_3390_cancers17091535 crossref_primary_10_1016_j_euros_2020_10_002 crossref_primary_10_1186_s12885_020_07754_9 crossref_primary_10_1038_s41391_020_00271_7 crossref_primary_10_3390_cancers14051152 crossref_primary_10_1038_s41391_022_00529_2 crossref_primary_10_1111_bju_14400 crossref_primary_10_1111_bju_14642 crossref_primary_10_1186_s13063_019_3322_7 crossref_primary_10_1055_a_0758_9944 crossref_primary_10_1016_j_euf_2018_11_008 crossref_primary_10_1111_andr_12578 crossref_primary_10_1016_j_cpet_2016_11_001 crossref_primary_10_1016_S0140_6736_24_00651_2 crossref_primary_10_1200_EDBK_278853 crossref_primary_10_1200_JCO_2017_76_4050 crossref_primary_10_3390_ijms222212095 crossref_primary_10_1016_j_tem_2020_12_004 crossref_primary_10_1016_j_annonc_2025_04_006 crossref_primary_10_1016_j_clon_2023_11_034 crossref_primary_10_1016_j_eururo_2017_07_030 crossref_primary_10_1016_j_eururo_2017_07_018 crossref_primary_10_1093_biomtc_ujaf019 crossref_primary_10_1111_iju_13372 crossref_primary_10_1007_s11912_018_0692_z crossref_primary_10_1111_bju_15507 crossref_primary_10_1111_iju_15550 crossref_primary_10_1111_bju_15988 crossref_primary_10_1016_j_acuro_2016_03_002 crossref_primary_10_1016_j_clon_2016_03_006 crossref_primary_10_1016_j_clon_2016_04_047 crossref_primary_10_5306_wjco_v12_i11_1009 crossref_primary_10_1016_j_bulcan_2018_06_005 crossref_primary_10_1007_s11912_025_01665_3 crossref_primary_10_1016_j_clgc_2017_08_006 crossref_primary_10_1016_j_urology_2020_12_021 crossref_primary_10_1016_j_ebiom_2020_102728 crossref_primary_10_1007_s10637_018_0660_3 crossref_primary_10_1177_20514158221088689 crossref_primary_10_1097_CU9_0000000000000118 crossref_primary_10_1055_a_2129_7206 crossref_primary_10_1200_EDBK_278845 crossref_primary_10_1002_jbm4_10187 crossref_primary_10_1016_j_ijrobp_2018_12_040 crossref_primary_10_3390_cancers12051199 crossref_primary_10_3389_fonc_2022_893980 crossref_primary_10_1177_1758835920985464 crossref_primary_10_1016_j_ctrv_2018_11_005 crossref_primary_10_2147_RRU_S303215 crossref_primary_10_1016_j_eururo_2018_02_021 crossref_primary_10_1016_j_eururo_2018_02_020 crossref_primary_10_3390_diagnostics10080520 crossref_primary_10_3390_medicines6030082 crossref_primary_10_1016_j_eururo_2021_01_037 crossref_primary_10_1016_j_euo_2022_04_007 crossref_primary_10_1016_j_euo_2022_04_009 crossref_primary_10_1111_ajco_12874 crossref_primary_10_1016_j_critrevonc_2016_04_014 crossref_primary_10_1038_s41391_017_0014_9 crossref_primary_10_1111_iju_14447 crossref_primary_10_2147_RRU_S360444 crossref_primary_10_1186_s13014_021_01849_8 crossref_primary_10_1007_s00120_019_0953_y crossref_primary_10_1016_j_urolonc_2018_03_010 crossref_primary_10_1016_j_clgc_2023_07_012 crossref_primary_10_2147_CMAR_S243843 crossref_primary_10_1158_1078_0432_CCR_20_0168 crossref_primary_10_1016_j_eururo_2018_02_013 crossref_primary_10_1007_s00066_016_1082_9 crossref_primary_10_1038_s41698_021_00174_3 crossref_primary_10_1016_j_ucl_2017_07_010 crossref_primary_10_1016_j_euros_2021_11_012 crossref_primary_10_1038_s41392_022_01042_7 crossref_primary_10_3389_fphys_2018_00500 crossref_primary_10_1097_CCO_0000000000000443 crossref_primary_10_1016_j_gendis_2025_101816 crossref_primary_10_3390_jcm11102853 crossref_primary_10_1016_j_ucl_2017_07_008 crossref_primary_10_1214_23_STS901 crossref_primary_10_1007_s00761_022_01109_8 crossref_primary_10_5534_wjmh_190044 crossref_primary_10_1016_j_ijso_2021_100419 crossref_primary_10_2217_cer_2018_0133 crossref_primary_10_3390_cancers12051178 crossref_primary_10_1007_s11307_017_1057_y crossref_primary_10_1016_j_euros_2021_10_003 crossref_primary_10_1007_s10585_019_09963_4 crossref_primary_10_1016_j_euo_2018_10_004 crossref_primary_10_1016_j_eururo_2018_01_043 crossref_primary_10_1016_j_canlet_2019_03_019 crossref_primary_10_1111_bju_13990 crossref_primary_10_1016_j_ejca_2024_114072 crossref_primary_10_1080_14656566_2020_1770726 crossref_primary_10_1007_s12149_022_01785_x crossref_primary_10_1016_j_acuro_2016_09_004 crossref_primary_10_3390_cancers14020440 crossref_primary_10_1016_j_heliyon_2023_e13827 crossref_primary_10_1080_10717544_2019_1686085 crossref_primary_10_1200_EDBK_239041 crossref_primary_10_1111_cas_13751 crossref_primary_10_1016_j_urolonc_2017_10_024 crossref_primary_10_1016_j_urolonc_2018_09_005 crossref_primary_10_2217_fon_2020_0315 crossref_primary_10_2217_fon_2020_0557 crossref_primary_10_1007_s11912_019_0791_5 crossref_primary_10_1038_s41598_023_42711_z crossref_primary_10_1016_j_euf_2018_12_001 crossref_primary_10_1007_s40487_020_00119_z crossref_primary_10_2217_fon_2018_0715 crossref_primary_10_1016_S0140_6736_21_02437_5 crossref_primary_10_1038_s41585_019_0243_x crossref_primary_10_1016_j_euo_2018_10_011 crossref_primary_10_1016_j_euf_2019_06_007 crossref_primary_10_1080_10408363_2023_2266482 crossref_primary_10_1177_1740774517725697 crossref_primary_10_1002_path_5652 crossref_primary_10_1186_s13550_020_00618_0 crossref_primary_10_1080_14796694_2025_2481024 crossref_primary_10_1634_theoncologist_2019_0495 crossref_primary_10_1038_s41391_019_0182_x crossref_primary_10_1002_cam4_71176 crossref_primary_10_1016_j_clgc_2025_102338 crossref_primary_10_1016_j_urolonc_2021_11_005 crossref_primary_10_1186_s13014_018_1037_7 crossref_primary_10_1038_s41391_020_0210_x crossref_primary_10_1159_000506693 crossref_primary_10_1093_jjco_hyab028 crossref_primary_10_1111_iju_14258 crossref_primary_10_1097_RLU_0000000000002799 crossref_primary_10_1007_s00761_019_0538_9 crossref_primary_10_1002_cncr_31626 crossref_primary_10_1016_j_clgc_2017_08_019 crossref_primary_10_1371_journal_pmed_1003629 crossref_primary_10_1002_phar_2084 crossref_primary_10_1007_s00520_017_3706_8 crossref_primary_10_1016_j_clgc_2017_08_011 crossref_primary_10_1093_jnci_djx013 crossref_primary_10_1016_j_urolonc_2016_05_002 crossref_primary_10_1002_onco_13848 crossref_primary_10_7759_cureus_81642 crossref_primary_10_1038_s41585_018_0077_y crossref_primary_10_1007_s00259_025_07431_8 crossref_primary_10_1016_j_eururo_2018_01_012 crossref_primary_10_1016_j_urology_2016_12_033 crossref_primary_10_1080_17512433_2018_1464388 crossref_primary_10_1186_s12885_020_06817_1 crossref_primary_10_1002_pros_70015 crossref_primary_10_1016_j_jbo_2018_10_004 crossref_primary_10_1007_s00345_016_1895_2 crossref_primary_10_1200_JCO_2016_69_0677 crossref_primary_10_3390_ijms22094712 crossref_primary_10_1016_j_clgc_2024_01_013 crossref_primary_10_1007_s00345_018_2615_x crossref_primary_10_1016_j_euros_2022_05_003 crossref_primary_10_1111_iju_13148 crossref_primary_10_1007_s00345_016_1818_2 crossref_primary_10_1016_j_ejca_2016_11_025 crossref_primary_10_1038_s41391_021_00339_y crossref_primary_10_1177_21582440251374958 crossref_primary_10_1016_j_acuro_2020_06_007 crossref_primary_10_1016_j_lpm_2017_03_007 crossref_primary_10_1038_s41585_019_0274_3 crossref_primary_10_2147_CMAR_S506423 crossref_primary_10_1016_j_bbadis_2021_166129 crossref_primary_10_1016_j_jgo_2019_10_005 crossref_primary_10_1016_j_radonc_2020_08_011 crossref_primary_10_1016_j_urolonc_2017_11_017 crossref_primary_10_1007_s00345_022_04030_2 crossref_primary_10_1002_cncr_31204 crossref_primary_10_1093_annonc_mdy122 crossref_primary_10_1177_2051415816685211 crossref_primary_10_1080_10543406_2023_2292211 crossref_primary_10_1038_s41391_021_00326_3 crossref_primary_10_1093_annonc_mdz210 crossref_primary_10_1007_s11298_023_3768_5 crossref_primary_10_3390_cancers14040892 crossref_primary_10_1001_jamanetworkopen_2023_36604 crossref_primary_10_1080_14656566_2018_1527312 crossref_primary_10_1016_j_ctro_2022_07_008 crossref_primary_10_1016_S1470_2045_24_00440_6 crossref_primary_10_1038_s41391_025_00936_1 crossref_primary_10_5534_wjmh_230104 crossref_primary_10_3390_cancers15051518 crossref_primary_10_1016_j_mpsur_2019_07_006 crossref_primary_10_1111_bju_14807 crossref_primary_10_1097_SPC_0000000000000280 crossref_primary_10_1177_1538574419828088 crossref_primary_10_1016_j_prro_2024_10_007 crossref_primary_10_1016_j_eururo_2019_08_014 crossref_primary_10_1007_s12325_018_0861_3 crossref_primary_10_1097_JU9_0000000000000137 crossref_primary_10_24060_2076_3093_2021_11_2_183_187 crossref_primary_10_1016_j_cct_2021_106481 crossref_primary_10_1016_j_critrevonc_2019_03_014 crossref_primary_10_1016_j_eururo_2019_08_010 crossref_primary_10_1177_1758835920920067 crossref_primary_10_1002_pros_23705 crossref_primary_10_1136_jitc_2021_002919 crossref_primary_10_1097_MOU_0000000000000778 crossref_primary_10_1007_s00259_018_4079_z crossref_primary_10_3390_genes10030240 crossref_primary_10_1111_iju_14605 crossref_primary_10_1016_j_euo_2018_09_005 crossref_primary_10_1111_iju_13512 crossref_primary_10_4103_jcrt_JCRT_23_20 crossref_primary_10_1016_j_ijrobp_2018_01_103 crossref_primary_10_3390_cancers13040677 crossref_primary_10_4103_1008_682X_179159 crossref_primary_10_1080_03007995_2018_1447450 crossref_primary_10_1097_MOU_0000000000000779 crossref_primary_10_1016_j_eururo_2016_12_025 crossref_primary_10_1038_s41598_019_57101_7 crossref_primary_10_1177_1756287218820804 crossref_primary_10_3389_fendo_2021_811578 crossref_primary_10_1016_j_euo_2022_06_003 crossref_primary_10_1016_j_urolonc_2018_08_016 crossref_primary_10_1080_17425255_2025_2478167 crossref_primary_10_1097_CCO_0000000000001128 crossref_primary_10_1177_1758835918776920 crossref_primary_10_1097_MOU_0000000000000784 crossref_primary_10_1002_cncr_30329 crossref_primary_10_1002_pros_23954 crossref_primary_10_1007_s12253_019_00789_9 crossref_primary_10_1093_jjco_hyae177 crossref_primary_10_1111_jfbc_12902 crossref_primary_10_1016_S0140_6736_16_31038_8 crossref_primary_10_1016_j_ijrobp_2018_10_005 crossref_primary_10_1080_14737140_2017_1374178 crossref_primary_10_1007_s11912_024_01509_6 crossref_primary_10_1016_j_euo_2019_02_007 crossref_primary_10_1016_j_clgc_2019_10_002 crossref_primary_10_1016_j_heliyon_2024_e29602 crossref_primary_10_1097_SPC_0000000000000216 crossref_primary_10_1172_JCI175680 crossref_primary_10_1148_radiol_2021204321 crossref_primary_10_1016_j_ejca_2017_07_007 crossref_primary_10_2217_fon_2020_1245 crossref_primary_10_3390_ijms26020679 crossref_primary_10_1016_j_eururo_2019_09_004 crossref_primary_10_1158_1078_0432_CCR_16_1361 crossref_primary_10_3389_fimmu_2022_996348 crossref_primary_10_3389_fonc_2021_659442 crossref_primary_10_1016_j_clgc_2018_02_016 crossref_primary_10_1007_s00120_019_01071_1 crossref_primary_10_1038_s41585_020_0298_8 crossref_primary_10_1016_j_tranon_2023_101807 crossref_primary_10_2147_OTT_S228355 crossref_primary_10_1016_j_clon_2016_06_006 crossref_primary_10_1200_JCO_2017_75_3657 crossref_primary_10_1016_j_clgc_2024_102096 crossref_primary_10_1186_s12894_019_0463_7 crossref_primary_10_1007_s00120_017_0464_7 crossref_primary_10_1016_j_eururo_2017_06_002 crossref_primary_10_1016_j_ejca_2021_04_025 crossref_primary_10_3390_ijms22042227 crossref_primary_10_1016_j_eururo_2021_03_004 crossref_primary_10_1038_s41585_018_0060_7 crossref_primary_10_1016_S0140_6736_15_01235_0 crossref_primary_10_3389_fonc_2020_627379 crossref_primary_10_1111_ecc_13140 crossref_primary_10_1186_s12885_022_09276_y crossref_primary_10_1200_GO_24_00042 crossref_primary_10_1016_j_annonc_2023_02_015 crossref_primary_10_1016_j_jpainsymman_2019_01_017 crossref_primary_10_1002_cncr_30374 crossref_primary_10_1007_s00120_020_01182_0 crossref_primary_10_1080_0284186X_2017_1423178 crossref_primary_10_1093_ajhp_zxac105 crossref_primary_10_1016_j_ijrobp_2020_06_009 crossref_primary_10_4103_iju_iju_60_23 crossref_primary_10_1016_j_annonc_2020_06_011 crossref_primary_10_1007_s40487_018_0088_0 crossref_primary_10_3390_biomedicines9050538 crossref_primary_10_1002_iju5_12512 crossref_primary_10_1016_j_annonc_2023_02_009 crossref_primary_10_1016_j_clon_2020_03_003 crossref_primary_10_1245_s10434_020_08407_8 crossref_primary_10_2217_fon_2020_0361 crossref_primary_10_1007_s00120_017_0366_8 crossref_primary_10_1038_s41391_023_00751_6 crossref_primary_10_1080_14796694_2025_2479374 crossref_primary_10_1097_MOU_0000000000000985 crossref_primary_10_1177_1758834017698644 crossref_primary_10_1016_j_acuroe_2024_05_008 crossref_primary_10_1186_s12014_020_09305_7 crossref_primary_10_1002_bco2_73 crossref_primary_10_1007_s40242_017_6450_1 crossref_primary_10_1016_j_urolonc_2024_07_002 crossref_primary_10_1016_j_eururo_2022_11_002 crossref_primary_10_1111_bju_13938 crossref_primary_10_1186_s13148_016_0264_8 crossref_primary_10_1080_14737140_2022_2139679 crossref_primary_10_3390_cancers15204945 crossref_primary_10_1038_s41416_023_02224_y crossref_primary_10_1056_NEJMoa1704174 crossref_primary_10_2147_CMAR_S425181 crossref_primary_10_1016_j_critrevonc_2019_05_005 crossref_primary_10_1111_bju_15055 crossref_primary_10_1016_j_euf_2022_08_007 crossref_primary_10_1016_j_path_2018_07_009 crossref_primary_10_3892_ol_2018_9321 crossref_primary_10_1007_s12032_018_1110_y crossref_primary_10_1002_pros_23645 crossref_primary_10_1097_CAD_0000000000000620 crossref_primary_10_1002_pros_23884 crossref_primary_10_1007_s00259_017_3887_x crossref_primary_10_1056_NEJMoa1903307 crossref_primary_10_1080_14737140_2016_1241148 crossref_primary_10_1080_14796694_2024_2442900 crossref_primary_10_1016_j_semradonc_2020_07_004 crossref_primary_10_1002_tre_824 crossref_primary_10_1097_COC_0000000000000520 crossref_primary_10_1016_j_semradonc_2020_07_005 crossref_primary_10_1186_s13014_021_01776_8 crossref_primary_10_1007_s40261_020_00888_5 crossref_primary_10_1097_COC_0000000000000526 crossref_primary_10_1093_jrr_rrad060 crossref_primary_10_1038_s41391_022_00556_z crossref_primary_10_3390_cancers14010051 crossref_primary_10_1096_fj_202501308RR crossref_primary_10_1097_JU_0000000000003370 crossref_primary_10_1038_nrurol_2016_225 crossref_primary_10_1016_j_ejca_2018_08_010 crossref_primary_10_1053_j_semnuclmed_2019_02_003 crossref_primary_10_2217_pgs_2022_0023 crossref_primary_10_1371_journal_pone_0259672 crossref_primary_10_3390_cancers9060067 crossref_primary_10_3389_fonc_2022_915171 crossref_primary_10_1007_s15015_018_3953_7 crossref_primary_10_1016_j_cell_2025_07_042 crossref_primary_10_1038_s41416_019_0681_5 crossref_primary_10_1002_pros_23430 crossref_primary_10_1007_s11914_021_00689_5 crossref_primary_10_1016_j_eururo_2021_05_016 crossref_primary_10_1186_s12885_021_08156_1 crossref_primary_10_1007_s00120_019_0925_2 crossref_primary_10_1038_s41585_022_00669_z crossref_primary_10_1136_jclinpath_2018_205404 crossref_primary_10_17650_1726_9776_2025_21_2_89_103 crossref_primary_10_1093_annonc_mdx410 crossref_primary_10_1002_pros_23666 crossref_primary_10_1007_s12325_021_01778_8 crossref_primary_10_52976_vansaglik_850376 crossref_primary_10_1002_cncr_31384 crossref_primary_10_1002_pros_23663 crossref_primary_10_1016_j_urolonc_2019_01_029 crossref_primary_10_26508_lsa_202000770 crossref_primary_10_1093_annonc_mdx637 crossref_primary_10_3389_fonc_2021_658331 crossref_primary_10_1016_j_radonc_2023_109746 crossref_primary_10_1016_j_ejca_2025_115293 crossref_primary_10_1007_s11033_021_06387_w crossref_primary_10_4103_ijmpo_ijmpo_55_20 crossref_primary_10_3389_fphar_2024_1399802 crossref_primary_10_1007_s10637_017_0433_4 crossref_primary_10_1016_j_eururo_2018_05_034 crossref_primary_10_1002_bco2_177 crossref_primary_10_1002_pros_23434 crossref_primary_10_48095_cccu2019021 crossref_primary_10_4103_UCCI_UCCI_2_24 crossref_primary_10_1016_j_bulcan_2020_01_010 crossref_primary_10_1016_j_canlet_2021_07_045 crossref_primary_10_1016_j_prnil_2018_10_002 crossref_primary_10_1111_bju_16106 crossref_primary_10_3390_cancers15194854 crossref_primary_10_1016_j_clon_2023_07_009 crossref_primary_10_1007_s12262_020_02213_y crossref_primary_10_1016_j_ejca_2019_04_031 crossref_primary_10_1097_MJT_0000000000001085 crossref_primary_10_2147_RRU_S398129 crossref_primary_10_3389_fonc_2017_00006 crossref_primary_10_1186_s13045_017_0485_0 crossref_primary_10_3390_ijms18071512 crossref_primary_10_1016_j_prnil_2020_07_007 crossref_primary_10_1038_s41585_018_0017_x crossref_primary_10_1158_1078_0432_CCR_18_0704 crossref_primary_10_1007_s44178_024_00118_4 crossref_primary_10_1016_j_annonc_2025_05_534 crossref_primary_10_3390_cancers14040967 crossref_primary_10_1007_s13629_020_00285_9 crossref_primary_10_1002_cam4_4372 crossref_primary_10_1200_JCO_2017_77_4315 crossref_primary_10_1038_s41467_020_15424_4 crossref_primary_10_1007_s11864_023_01094_z crossref_primary_10_1080_19466315_2025_2496316 crossref_primary_10_3390_ijms23010004 crossref_primary_10_1002_bco2_116 crossref_primary_10_1016_j_ijrobp_2022_09_075 crossref_primary_10_1007_s12094_019_02274_w crossref_primary_10_1097_JS9_0000000000001884 crossref_primary_10_3389_fonc_2021_769068 crossref_primary_10_1038_nrurol_2016_273 crossref_primary_10_1093_jnci_djab196 crossref_primary_10_1007_s11523_018_0588_8 crossref_primary_10_1007_s00120_017_0505_2 crossref_primary_10_1038_nrurol_2016_270 crossref_primary_10_1136_ejhpharm_2019_001955 crossref_primary_10_3390_medsci10010015 crossref_primary_10_1016_j_euros_2021_08_008 crossref_primary_10_1016_j_clgc_2022_02_009 crossref_primary_10_1016_j_jgo_2022_11_010 crossref_primary_10_1016_j_eururo_2021_06_011 crossref_primary_10_1080_17512433_2017_1345624 crossref_primary_10_1111_cas_15038 crossref_primary_10_1002_cncr_32039 crossref_primary_10_1016_j_clgc_2018_05_006 crossref_primary_10_1186_s12885_020_06844_y crossref_primary_10_3389_fonc_2019_00572 crossref_primary_10_1016_j_acuro_2021_10_003 crossref_primary_10_1016_j_eclinm_2024_102914 crossref_primary_10_1016_j_eururo_2017_09_022 crossref_primary_10_1016_j_urolonc_2021_05_020 crossref_primary_10_3389_fonc_2023_1130680 crossref_primary_10_1016_j_pharmthera_2017_05_009 crossref_primary_10_1016_j_ejca_2021_06_005 crossref_primary_10_1186_s12913_021_06266_x crossref_primary_10_4103_HUAJ_HUAJ_19_20 crossref_primary_10_1016_j_ebiom_2017_12_024 crossref_primary_10_1016_j_canlet_2021_06_010 crossref_primary_10_1016_j_eururo_2017_09_029 crossref_primary_10_1016_j_semcancer_2017_03_009 crossref_primary_10_1002_pros_24718 crossref_primary_10_1097_SPC_0000000000000507 crossref_primary_10_1097_SPC_0000000000000749 crossref_primary_10_1080_14656566_2021_1925647 crossref_primary_10_1177_17407745231206261 crossref_primary_10_1016_j_brachy_2018_07_009 crossref_primary_10_3390_cancers13112844 crossref_primary_10_1007_s00345_018_2236_4 crossref_primary_10_1200_JCO_18_02158 crossref_primary_10_1016_j_clgc_2023_08_006 crossref_primary_10_1016_j_eururo_2021_06_023 crossref_primary_10_1007_s00223_017_0353_5 crossref_primary_10_1016_j_clgc_2024_102138 crossref_primary_10_1097_CAD_0000000000000438 crossref_primary_10_1016_j_bulcan_2019_11_006 crossref_primary_10_1007_s12254_018_0393_1 crossref_primary_10_1016_j_soncn_2025_151914 crossref_primary_10_1038_s41585_020_0310_3 crossref_primary_10_1002_pros_23251 crossref_primary_10_1002_pros_23493 crossref_primary_10_1007_s00345_018_2449_6 crossref_primary_10_1186_s13643_022_02137_6 crossref_primary_10_3390_cancers11121908 crossref_primary_10_2196_11625 crossref_primary_10_1016_j_semcancer_2018_09_003 crossref_primary_10_1080_14737140_2021_1856661 crossref_primary_10_3390_cells8121619 crossref_primary_10_1038_pcan_2016_26 crossref_primary_10_1080_14737140_2023_2171991 crossref_primary_10_1016_j_eururo_2020_09_046 crossref_primary_10_1038_pcan_2016_31 crossref_primary_10_36290_xon_2019_029 crossref_primary_10_1002_pros_24352 crossref_primary_10_1007_s00120_017_0338_z crossref_primary_10_1007_s10585_020_10043_1 crossref_primary_10_1016_j_eururo_2018_12_042 crossref_primary_10_1177_1756287216686018 crossref_primary_10_1007_s12032_020_01385_7 crossref_primary_10_1007_s00259_020_04777_z crossref_primary_10_1016_j_ctrv_2016_02_002 crossref_primary_10_1016_j_eururo_2018_03_028 crossref_primary_10_1016_j_eururo_2018_11_001 crossref_primary_10_12688_f1000research_15382_1 crossref_primary_10_2478_prolas_2021_0024 crossref_primary_10_1016_j_semradonc_2021_03_007 crossref_primary_10_1016_S0140_6736_22_00367_1 crossref_primary_10_1038_pcan_2016_40 crossref_primary_10_1007_s00345_019_02974_6 crossref_primary_10_1093_jjco_hyaa030 crossref_primary_10_4103_ijc_ijc_1145_21 crossref_primary_10_1016_j_euf_2018_01_009 crossref_primary_10_1016_j_euf_2018_01_006 crossref_primary_10_1055_a_1332_8625 crossref_primary_10_3390_cancers14010223 crossref_primary_10_1002_pros_24369 crossref_primary_10_1016_j_euf_2016_09_001 crossref_primary_10_1186_s13063_019_3216_8 crossref_primary_10_1007_s11845_023_03303_y crossref_primary_10_1016_j_clgc_2022_11_001 crossref_primary_10_1200_JCO_19_01595 crossref_primary_10_3390_cancers11091390 crossref_primary_10_1016_j_euo_2023_12_012 crossref_primary_10_1016_j_eururo_2018_11_034 crossref_primary_10_1038_s41391_022_00598_3 crossref_primary_10_1016_j_bone_2021_115907 crossref_primary_10_1016_j_eururo_2018_11_030 crossref_primary_10_1093_clinchem_hvaa095 crossref_primary_10_1093_jjco_hyab115 crossref_primary_10_1007_s11934_018_0835_7 crossref_primary_10_2217_fon_2019_0190 crossref_primary_10_1038_s41571_019_0284_3 crossref_primary_10_1111_bju_14398 crossref_primary_10_1111_bju_16577 crossref_primary_10_1016_j_ucl_2020_07_004 crossref_primary_10_1016_S1470_2045_16_30572_1 crossref_primary_10_1111_bju_14152 crossref_primary_10_1186_s12014_025_09543_7 crossref_primary_10_23736_S1824_4785_19_03160_1 crossref_primary_10_3390_biom11040492 crossref_primary_10_1111_bju_14395 crossref_primary_10_3390_diagnostics11010117 crossref_primary_10_1177_17588359211051870 crossref_primary_10_1002_cam4_981 crossref_primary_10_1002_cam4_70226 crossref_primary_10_1007_s11695_021_05739_6 crossref_primary_10_1016_j_euo_2020_07_001 crossref_primary_10_3390_cells10051133 crossref_primary_10_1016_j_euros_2024_03_012 crossref_primary_10_1016_j_euo_2020_07_004 crossref_primary_10_1177_1756287218808496 crossref_primary_10_1016_j_acuroe_2021_10_005 crossref_primary_10_1186_s12916_019_1391_9 crossref_primary_10_1002_ijc_31346 crossref_primary_10_1177_17407745221112001 crossref_primary_10_1016_j_euf_2022_09_002 crossref_primary_10_1016_j_eururo_2018_02_001 crossref_primary_10_3390_cancers14010008 crossref_primary_10_1093_jncics_pkac044 crossref_primary_10_1093_jncics_pkac043 crossref_primary_10_1111_ajco_13060 crossref_primary_10_1200_JCO_2016_67_4788 crossref_primary_10_1007_s40336_021_00421_4 crossref_primary_10_1155_2022_7711555 crossref_primary_10_1007_s00092_018_1736_2 crossref_primary_10_1038_pcan_2016_71 crossref_primary_10_1111_imj_14262 crossref_primary_10_1016_j_urolonc_2019_04_030 crossref_primary_10_1200_JCO_2016_71_8486 crossref_primary_10_1007_s00092_019_2061_0 crossref_primary_10_1016_j_ejca_2021_09_036 crossref_primary_10_1097_MJT_0000000000001008 crossref_primary_10_3389_fonc_2024_1475178 crossref_primary_10_1016_j_canlet_2021_11_033 crossref_primary_10_1016_j_euo_2023_05_002 crossref_primary_10_1038_s41391_021_00389_2 crossref_primary_10_3390_curroncol32060331 crossref_primary_10_1080_0284186X_2023_2257876 crossref_primary_10_1093_jjco_hyaa225 crossref_primary_10_1007_s11136_019_02117_9 crossref_primary_10_1080_17425255_2018_1440288 crossref_primary_10_1111_ajco_13057 crossref_primary_10_1111_bju_15669 crossref_primary_10_1158_1078_0432_CCR_22_2998 crossref_primary_10_3390_cancers14092326 crossref_primary_10_1111_bju_14576 crossref_primary_10_1016_j_canrad_2019_06_018 crossref_primary_10_1177_17588359221086827 crossref_primary_10_1016_j_euf_2018_02_004 crossref_primary_10_1016_j_urolonc_2024_03_003 crossref_primary_10_1038_s41585_021_00445_5 crossref_primary_10_1007_s10555_024_10236_0 crossref_primary_10_1016_j_euf_2016_08_011 crossref_primary_10_1002_sim_70162 crossref_primary_10_1007_s43441_021_00315_7 crossref_primary_10_1002_pros_24329 crossref_primary_10_1038_s41419_022_05289_4 crossref_primary_10_1016_j_ijpharm_2023_122704 crossref_primary_10_3390_ijms25010078 crossref_primary_10_1177_1758834017692779 crossref_primary_10_3389_fimmu_2024_1434300 crossref_primary_10_1093_jbmrpl_ziae157 crossref_primary_10_1159_000545854 crossref_primary_10_1016_j_clgc_2022_04_014 crossref_primary_10_1016_j_ctrv_2019_05_003 crossref_primary_10_2147_OTT_S306345 crossref_primary_10_3390_diagnostics11020345 crossref_primary_10_1002_pros_24312 crossref_primary_10_1007_s10147_024_02485_4 crossref_primary_10_1016_j_eursup_2017_09_005 crossref_primary_10_1177_11795549241277181 crossref_primary_10_1186_s13550_021_00805_7 crossref_primary_10_1177_17588359221092486 crossref_primary_10_1016_j_clgc_2018_07_014 crossref_primary_10_1016_j_clgc_2018_07_017 crossref_primary_10_1002_cam4_5640 crossref_primary_10_1016_j_canlet_2024_216776 crossref_primary_10_1016_j_ctrv_2018_04_014 crossref_primary_10_3390_cancers15235615 crossref_primary_10_1016_j_clgc_2021_03_022 crossref_primary_10_1016_j_ijrobp_2017_07_041 crossref_primary_10_1093_jncics_pkac049 crossref_primary_10_1016_j_canlet_2019_01_010 crossref_primary_10_1016_S1470_2045_19_30082_8 crossref_primary_10_3390_cancers12010189 crossref_primary_10_1002_pros_23476 crossref_primary_10_1186_s13046_018_0987_9 crossref_primary_10_1158_1078_0432_CCR_19_2389 crossref_primary_10_1016_S0140_6736_18_32486_3 crossref_primary_10_1007_s00432_019_03085_w crossref_primary_10_1016_j_ejca_2017_11_021 crossref_primary_10_1016_j_eururo_2018_10_042 crossref_primary_10_1158_1078_0432_CCR_20_3587 crossref_primary_10_1038_s41598_017_06142_x crossref_primary_10_1111_pin_12997 crossref_primary_10_17650_1726_9776_2018_14_2_130_141 crossref_primary_10_1111_bju_15851 crossref_primary_10_1016_j_jbo_2020_100311 crossref_primary_10_1016_S1470_2045_19_30155_X crossref_primary_10_1186_s40164_023_00444_9 crossref_primary_10_1016_j_prnil_2021_06_001 crossref_primary_10_1002_cncr_30631 crossref_primary_10_1159_000519861 crossref_primary_10_1016_j_ctarc_2020_100256 crossref_primary_10_1016_j_canlet_2022_216011 crossref_primary_10_1016_j_eururo_2022_03_031 crossref_primary_10_1016_j_ijrobp_2019_11_418 crossref_primary_10_1056_NEJMe1704992 crossref_primary_10_1056_NEJMra1701695 crossref_primary_10_3390_cells8010043 crossref_primary_10_1016_S1470_2045_23_00148_1 crossref_primary_10_1007_s12032_018_1238_9 crossref_primary_10_1016_j_acuroe_2017_03_001 crossref_primary_10_1186_s12885_022_10374_0 crossref_primary_10_1007_s12094_021_02561_5 crossref_primary_10_1093_oncolo_oyad046 crossref_primary_10_1093_oncolo_oyad045 crossref_primary_10_1177_15330338211035260 crossref_primary_10_1200_JCO_2017_72_4138 crossref_primary_10_3390_cancers16111974 crossref_primary_10_1007_s40273_016_0457_1 crossref_primary_10_1111_bju_13682 crossref_primary_10_3389_fonc_2019_01273 crossref_primary_10_3390_cancers15205008 crossref_primary_10_1159_000513073 crossref_primary_10_1161_CIRCULATIONAHA_121_056810 crossref_primary_10_7759_cureus_91143 crossref_primary_10_1093_annonc_mdy072 crossref_primary_10_1002_cncr_30620 crossref_primary_10_1016_j_prnil_2022_01_004 crossref_primary_10_1007_s12032_018_1105_8 crossref_primary_10_1093_annonc_mdy071 crossref_primary_10_1016_j_euo_2024_01_016 crossref_primary_10_1016_j_eururo_2019_03_004 crossref_primary_10_1016_j_clgc_2020_08_002 crossref_primary_10_1038_s41585_021_00447_3 crossref_primary_10_1002_iju5_70082 crossref_primary_10_3390_cancers11111719 crossref_primary_10_12998_wjcc_v10_i11_3461 crossref_primary_10_1016_j_ebiom_2019_03_032 crossref_primary_10_1093_postmj_qgae063 crossref_primary_10_1186_s12885_021_09018_6 crossref_primary_10_1200_JCO_2017_75_3335 crossref_primary_10_1111_bju_15632 crossref_primary_10_1038_s41391_021_00445_x crossref_primary_10_1007_s11523_018_0611_0 crossref_primary_10_1016_j_clgc_2016_07_004 crossref_primary_10_1016_j_clgc_2019_05_001 crossref_primary_10_1016_j_eururo_2016_06_041 crossref_primary_10_1007_s15004_020_8312_0 crossref_primary_10_1016_j_canep_2019_101628 crossref_primary_10_3390_cancers13164209 crossref_primary_10_2217_fon_2022_0914 crossref_primary_10_1016_j_prnil_2020_12_003 crossref_primary_10_1007_s00066_025_02458_0 crossref_primary_10_1007_s11604_025_01816_3 crossref_primary_10_1016_j_eururo_2015_11_030 crossref_primary_10_1148_rg_2020200058 crossref_primary_10_1007_s10853_024_09923_8 crossref_primary_10_1016_j_medj_2024_09_009 crossref_primary_10_1093_annonc_mdz396 crossref_primary_10_1016_j_ejmech_2022_114435 crossref_primary_10_3390_cancers12102854 crossref_primary_10_1007_s00345_019_02872_x crossref_primary_10_1200_JGO_18_00009 crossref_primary_10_1002_iju5_12031 crossref_primary_10_1016_j_eururo_2018_09_008 crossref_primary_10_1080_03007995_2017_1308919 crossref_primary_10_1001_jamanetworkopen_2023_27637 crossref_primary_10_3389_fonc_2020_01381 crossref_primary_10_1007_s11523_020_00734_w crossref_primary_10_1093_ecco_jcc_jjaa137 crossref_primary_10_1016_j_urolonc_2019_05_017 crossref_primary_10_1007_s11523_020_00756_4 crossref_primary_10_1111_iju_15647 crossref_primary_10_1002_pros_24269 crossref_primary_10_1016_j_urology_2017_04_062 crossref_primary_10_1111_iju_15243 crossref_primary_10_3389_fmolb_2022_997659 crossref_primary_10_1016_j_acuroe_2024_10_005 crossref_primary_10_1007_s00120_025_02583_9 crossref_primary_10_1111_iju_15240 crossref_primary_10_1007_s00259_019_04581_4 crossref_primary_10_1080_0284186X_2022_2051204 crossref_primary_10_1146_annurev_med_051517_011947 crossref_primary_10_3390_ijms19092545 crossref_primary_10_3390_cancers9020013 crossref_primary_10_1007_s00120_020_01381_9 crossref_primary_10_1007_s00345_019_03060_7 crossref_primary_10_1016_j_urolonc_2020_07_012 crossref_primary_10_1016_j_ctrv_2022_102441 crossref_primary_10_1016_j_euros_2024_10_010 crossref_primary_10_1002_pros_24257 crossref_primary_10_1080_14737140_2021_1852932 crossref_primary_10_3390_cancers14194757 crossref_primary_10_1080_14737140_2022_2082947 crossref_primary_10_3390_cancers13174257 crossref_primary_10_1016_j_urolonc_2018_10_007 crossref_primary_10_1080_14737159_2018_1427068 crossref_primary_10_1007_s11095_019_2730_4 crossref_primary_10_1016_j_eururo_2016_06_008 crossref_primary_10_1080_17425255_2024_2353749 crossref_primary_10_3390_cancers14081959 crossref_primary_10_1093_jjco_hyac016 crossref_primary_10_1016_j_ipha_2024_07_001 crossref_primary_10_1002_uro2_22 crossref_primary_10_1007_s11654_017_0010_5 crossref_primary_10_1093_oncolo_oyab057 crossref_primary_10_3389_fphar_2024_1442227 crossref_primary_10_1016_j_mednuc_2023_09_004 crossref_primary_10_1038_s41598_020_71263_9 crossref_primary_10_1055_a_1851_3276 crossref_primary_10_1080_14737140_2020_1770087 crossref_primary_10_1016_j_mednuc_2023_09_003 crossref_primary_10_1200_EDBK_390166 crossref_primary_10_1038_s41391_021_00469_3 crossref_primary_10_3389_fonc_2022_913438 crossref_primary_10_1016_j_prnil_2023_10_003 crossref_primary_10_1186_s13550_020_00728_9 crossref_primary_10_1001_jamanetworkopen_2023_36390 crossref_primary_10_1200_EDBK_200967 crossref_primary_10_1038_s41391_021_00436_y crossref_primary_10_1634_theoncologist_2018_0621 crossref_primary_10_1007_s11912_017_0568_7 crossref_primary_10_1007_s00345_022_04200_2 crossref_primary_10_1002_pros_24053 crossref_primary_10_2217_fon_2018_0619 crossref_primary_10_1016_j_clgc_2019_06_001 crossref_primary_10_1038_s41391_024_00897_x crossref_primary_10_1093_oncolo_oyab045 crossref_primary_10_3390_cancers16183187 crossref_primary_10_1007_s11912_022_01323_y crossref_primary_10_1016_j_ijpharm_2024_123808 crossref_primary_10_1080_14656566_2018_1444028 crossref_primary_10_1111_cas_14722 crossref_primary_10_1016_j_jval_2021_10_016 crossref_primary_10_1080_03007995_2021_1879753 crossref_primary_10_1200_EDBK_390396 crossref_primary_10_1016_j_acuro_2016_11_008 crossref_primary_10_4103_UROS_UROS_11_18 crossref_primary_10_1016_S1473_3099_16_30315_2 crossref_primary_10_1038_s41585_023_00845_9 crossref_primary_10_1097_CCO_0000000000000520 crossref_primary_10_1016_j_euo_2018_03_002 crossref_primary_10_4103_jcrt_JCRT_342_19 crossref_primary_10_1200_JCO_2018_78_2151 crossref_primary_10_3892_ol_2025_15046 crossref_primary_10_3390_pharmaceutics13050623 crossref_primary_10_4103_iju_IJU_238_20 crossref_primary_10_1038_onc_2016_482 crossref_primary_10_1016_j_clgc_2025_102438 crossref_primary_10_4103_aja202320 crossref_primary_10_1007_s00345_016_1906_3 crossref_primary_10_1038_s41391_020_0255_x crossref_primary_10_1016_j_acuroe_2017_05_007 crossref_primary_10_1007_s15004_019_6752_1 crossref_primary_10_1002_cam4_1735 crossref_primary_10_1016_j_clgc_2024_102152 crossref_primary_10_1016_j_eururo_2018_07_027 crossref_primary_10_1016_j_tranon_2021_101177 crossref_primary_10_1016_j_annonc_2021_06_003 crossref_primary_10_1017_S0029665123000046 crossref_primary_10_1002_ijc_34018 crossref_primary_10_1080_07853890_2018_1514529 crossref_primary_10_1016_j_eururo_2020_01_012 crossref_primary_10_1002_cam4_6188 crossref_primary_10_1016_j_euf_2017_11_009 crossref_primary_10_1634_theoncologist_2016_0161 crossref_primary_10_1016_j_clgc_2020_06_001 crossref_primary_10_1002_sim_7367 crossref_primary_10_1136_bmjopen_2020_042953 crossref_primary_10_1080_14728214_2018_1459563 crossref_primary_10_1186_s13104_021_05641_5 crossref_primary_10_15342_ijms_v6ir_292 crossref_primary_10_1016_j_ctrv_2018_09_006 crossref_primary_10_1016_S0140_6736_22_00427_5 crossref_primary_10_1080_14737140_2025_2509760 crossref_primary_10_3390_cancers17132249 crossref_primary_10_1111_bju_14936 crossref_primary_10_3390_cells9020460 crossref_primary_10_1016_j_euf_2018_09_015 crossref_primary_10_1038_s41598_018_26050_y crossref_primary_10_3389_fpubh_2022_952739 crossref_primary_10_1007_s12032_017_1050_y crossref_primary_10_1038_s41392_024_01760_0 crossref_primary_10_3389_fonc_2022_1060864 crossref_primary_10_1186_s13073_022_01080_4 crossref_primary_10_1016_j_ccell_2017_06_007 crossref_primary_10_1016_j_ijrobp_2016_06_2453 crossref_primary_10_1080_14737159_2019_1665998 crossref_primary_10_1177_1756287218786160 crossref_primary_10_1016_j_urolonc_2018_12_007 crossref_primary_10_1038_s41392_020_0109_y crossref_primary_10_1136_bmjopen_2021_048996 crossref_primary_10_1016_j_clon_2017_06_006 crossref_primary_10_1016_j_euo_2020_11_001 crossref_primary_10_1016_j_euo_2024_03_007 crossref_primary_10_1016_S0140_6736_24_01865_8 crossref_primary_10_2217_fon_2019_0509 crossref_primary_10_1016_j_urology_2019_03_040 crossref_primary_10_1038_s41585_019_0251_x crossref_primary_10_1007_s10147_019_01559_y crossref_primary_10_3389_fmed_2024_1460212 crossref_primary_10_4103_aja20242 crossref_primary_10_1016_j_euo_2021_04_008 crossref_primary_10_1200_JCO_2016_68_4738 crossref_primary_10_1038_s41391_019_0190_x crossref_primary_10_1016_j_eururo_2022_04_002 crossref_primary_10_3390_cells9112342 crossref_primary_10_1016_j_clon_2021_04_008 crossref_primary_10_1073_pnas_1910952117 crossref_primary_10_1200_JCO_2018_78_0619 crossref_primary_10_1016_j_radonc_2018_06_027 crossref_primary_10_3389_fonc_2025_1468928 crossref_primary_10_3390_jcm8040489 crossref_primary_10_1007_s00280_020_04063_7 crossref_primary_10_3390_biomedicines9040430 crossref_primary_10_1016_j_acuro_2024_03_002 crossref_primary_10_1016_j_soncn_2020_151047 crossref_primary_10_1016_j_clgc_2018_10_010 crossref_primary_10_1007_s00761_021_01024_4 crossref_primary_10_1111_bju_14711 crossref_primary_10_1016_j_eururo_2020_01_026 crossref_primary_10_1002_pros_24915 crossref_primary_10_1016_j_ctrv_2016_06_005 crossref_primary_10_1001_jamanetworkopen_2024_48707 crossref_primary_10_1016_j_urolonc_2019_07_005 crossref_primary_10_1158_0008_5472_CAN_17_3006 crossref_primary_10_1038_s41391_020_0233_3 crossref_primary_10_1016_j_canlet_2021_08_033 crossref_primary_10_1016_j_urolonc_2019_07_009 crossref_primary_10_1177_2051415821993760 crossref_primary_10_3390_md15030066 crossref_primary_10_3390_cancers14030503 crossref_primary_10_1016_j_eururo_2018_07_022 crossref_primary_10_1080_17512433_2017_1321985 crossref_primary_10_3390_diagnostics15131682 crossref_primary_10_1016_j_jgo_2023_101621 crossref_primary_10_3390_cancers15061691 crossref_primary_10_1016_j_ctrv_2018_08_005 crossref_primary_10_2217_fon_2017_0430 crossref_primary_10_1016_j_ijrobp_2018_02_005 crossref_primary_10_1016_j_prnil_2019_10_003 crossref_primary_10_3390_cancers13194951 crossref_primary_10_1016_j_semradonc_2016_08_003 crossref_primary_10_1080_14737159_2020_1702522 crossref_primary_10_1186_s13073_020_00770_1 crossref_primary_10_3390_cells9061362 crossref_primary_10_1007_s40487_021_00181_1 crossref_primary_10_1038_s41416_023_02417_5 crossref_primary_10_1016_j_semradonc_2016_08_005 crossref_primary_10_1016_S1470_2045_16_30227_3 crossref_primary_10_1007_s10637_016_0357_4 crossref_primary_10_1007_s12254_018_0386_0 crossref_primary_10_1016_j_urolonc_2023_05_006 crossref_primary_10_1371_journal_pone_0228447 crossref_primary_10_5534_wjmh_220200 crossref_primary_10_1002_cncr_33543 crossref_primary_10_1158_1078_0432_CCR_21_0685 crossref_primary_10_30621_jbachs_1057317 crossref_primary_10_1186_s13063_016_1488_9 crossref_primary_10_1186_s13063_024_07989_y crossref_primary_10_1080_17425255_2017_1405934 crossref_primary_10_1016_j_eururo_2017_12_021 crossref_primary_10_3390_ph17030351 crossref_primary_10_2217_fon_2017_0445 crossref_primary_10_1016_j_crad_2019_05_003 crossref_primary_10_3390_cancers13061290 crossref_primary_10_47248_chp2502030014 crossref_primary_10_1007_s00120_020_01411_6 crossref_primary_10_1016_j_ejca_2016_06_026 crossref_primary_10_1007_s40258_023_00866_w crossref_primary_10_1093_jnci_djad192 crossref_primary_10_1097_CAD_0000000000000375 crossref_primary_10_3390_cancers13030546 crossref_primary_10_1186_s40364_022_00393_1 crossref_primary_10_1002_cncr_31355 crossref_primary_10_1007_s13629_024_00419_3 crossref_primary_10_1016_j_urology_2017_02_051 crossref_primary_10_3390_jpm14050517 crossref_primary_10_1016_j_euros_2022_10_020 crossref_primary_10_1038_nrurol_2017_115 crossref_primary_10_1016_j_jons_2019_06_001 crossref_primary_10_1080_14656566_2019_1574754 crossref_primary_10_1016_j_eururo_2018_08_013 crossref_primary_10_1016_j_urolonc_2022_10_016 crossref_primary_10_1097_SPC_0000000000000359 crossref_primary_10_1097_SPC_0000000000000356 crossref_primary_10_1016_j_tranon_2019_10_012 crossref_primary_10_1016_j_ctrv_2019_01_005 crossref_primary_10_1038_s41598_021_91876_y crossref_primary_10_1016_j_ejca_2021_11_026 crossref_primary_10_1016_j_jclinepi_2020_04_025 crossref_primary_10_4103_aja202173 crossref_primary_10_1016_j_urolonc_2019_09_028 crossref_primary_10_3389_fonc_2021_778858 crossref_primary_10_1016_j_clgc_2020_05_003 crossref_primary_10_1016_j_crad_2019_06_009 crossref_primary_10_1093_brain_awad063 crossref_primary_10_1016_j_eururo_2018_09_048 crossref_primary_10_1007_s00345_019_02661_6 crossref_primary_10_5301_tj_5000583 crossref_primary_10_5306_wjco_v12_i2_43 crossref_primary_10_1038_nrurol_2016_4 crossref_primary_10_1007_s00134_017_4821_1 crossref_primary_10_1016_j_ctarc_2022_100606 crossref_primary_10_1016_j_euo_2020_10_009 crossref_primary_10_1016_j_tranon_2023_101701 crossref_primary_10_1097_CAD_0000000000001491 crossref_primary_10_1007_s13629_019_00260_z crossref_primary_10_1007_s00120_019_01072_0 crossref_primary_10_1007_s00761_019_0606_1 crossref_primary_10_1016_j_urolonc_2017_06_046 crossref_primary_10_1080_14737140_2020_1732212 crossref_primary_10_1007_s12325_016_0351_4 crossref_primary_10_1016_S1470_2045_16_00149_2 crossref_primary_10_3390_cancers14246194 crossref_primary_10_4103_iju_IJU_258_19 crossref_primary_10_1016_j_eururo_2016_05_030 crossref_primary_10_1089_cbr_2019_3493 |
| Cites_doi | 10.1186/1745-6215-15-364 10.1093/jnci/djh141 10.1056/NEJMoa040720 10.1016/j.clon.2008.07.002 10.1056/NEJMoa1001294 10.1016/S1470-2045(12)70088-8 10.1016/j.eururo.2014.09.032 10.1056/NEJMoa1014618 10.1002/cncr.28270 10.1200/JCO.2010.30.7025 10.1016/j.clgc.2015.01.010 10.1200/JCO.2006.06.4451 10.1056/NEJMoa1213755 10.1186/1745-6215-13-168 10.1002/sim.1203 10.2307/2533376 10.1016/j.ejca.2010.10.013 10.1056/NEJMoa1405095 10.1016/j.eururo.2014.02.014 10.1056/NEJMoa1207506 10.2307/2983471 10.1056/NEJMoa041318 10.1016/S1470-2045(09)70201-3 10.1186/1745-6215-10-39 10.1200/jco.2015.33.7_suppl.140 10.1016/S0140-6736(10)61389-X 10.1016/S1470-2045(14)70328-6 10.1093/jnci/djn267 10.1016/S1470-2045(12)70560-0 10.1056/NEJMoa1503747 10.1200/jco.2014.32.15_suppl.5005 10.1056/NEJMoa0809003 10.1177/1536867X0900900401 |
| ContentType | Journal Article |
| Contributor | Churn, Mark Adab, Fawzi Beesley, Sharon Alonzi, Roberto Chowdhury, Simon Banerjee, Gautam Cowan, Richard Andrews, Stephen Bertelli, Gianfilippo Brown Richard, B Hingorani, Mohan Hughes, Robert Hamid, Abdel Gale, Joanna Bahl, Amit Bhana, Rajanee Crellin, Perric Choudhurey, Ananya Clarke, Noel Hill, Esme Henry, Ann Ferguson, Catherine Castell, Fiona Ford, Daniel Andrade, Gerard Chan, Andrew Graham, John D Beaney, Ronald Chetiyawardana, Shan Baria, Karin Herbert, Chris Crabb, Simon Chadwick, Eliot Ansari, Jawaher Anyamene, Nicola Harper, Peter Huddart, Robert Charnley, Natalie Gibbs, Stephanie Bloomfield, David Hamilton, Joanna Ibrahim, Azman Eswar, Chinnamani Chan, Olivia Frim, Olivera Alzouebi, Mymoona Grant, Warren Button, Michael Ahmed, Imtiaz Dickson, Jeanette Jain, Suneil Al-hasso, Abdulla Glen, Hilary Brierly, Robert Jenkins, Peter Cross, William Hetherington, John Hilman, Serena Hughes, Simon Alcock, Christopher Eichholz, Andrew Choudhury, Ananya Davies, Joe Beresford, Mark Das, Tathagata Falconer, Alison Ballesteros-Quintail, David Crawford, Mic |
| Contributor_xml | – sequence: 1 givenname: Fawzi surname: Adab fullname: Adab, Fawzi – sequence: 2 givenname: Adebanji surname: Adeyoju fullname: Adeyoju, Adebanji – sequence: 3 givenname: Imtiaz surname: Ahmed fullname: Ahmed, Imtiaz – sequence: 4 givenname: Christopher surname: Alcock fullname: Alcock, Christopher – sequence: 5 givenname: Abdulla surname: Al-hasso fullname: Al-hasso, Abdulla – sequence: 6 givenname: Roberto surname: Alonzi fullname: Alonzi, Roberto – sequence: 7 givenname: Mymoona surname: Alzouebi fullname: Alzouebi, Mymoona – sequence: 8 givenname: Gerard surname: Andrade fullname: Andrade, Gerard – sequence: 9 givenname: Stephen surname: Andrews fullname: Andrews, Stephen – sequence: 10 givenname: Jawaher surname: Ansari fullname: Ansari, Jawaher – sequence: 11 givenname: Nicola surname: Anyamene fullname: Anyamene, Nicola – sequence: 12 givenname: Ashraf surname: Azzabi fullname: Azzabi, Ashraf – sequence: 13 givenname: Amit surname: Bahl fullname: Bahl, Amit – sequence: 14 givenname: David surname: Ballesteros-Quintail fullname: Ballesteros-Quintail, David – sequence: 15 givenname: Gautam surname: Banerjee fullname: Banerjee, Gautam – sequence: 16 givenname: Jim surname: Barber fullname: Barber, Jim – sequence: 17 givenname: Karin surname: Baria fullname: Baria, Karin – sequence: 18 givenname: Ronald surname: Beaney fullname: Beaney, Ronald – sequence: 19 givenname: Sharon surname: Beesley fullname: Beesley, Sharon – sequence: 20 givenname: Mark surname: Beresford fullname: Beresford, Mark – sequence: 21 givenname: Gianfilippo surname: Bertelli fullname: Bertelli, Gianfilippo – sequence: 22 givenname: Neeraj surname: Bhalla fullname: Bhalla, Neeraj – sequence: 23 givenname: Rajanee surname: Bhana fullname: Bhana, Rajanee – sequence: 24 givenname: Alison surname: Birtle fullname: Birtle, Alison – sequence: 25 givenname: David surname: Bloomfield fullname: Bloomfield, David – sequence: 26 givenname: Jo surname: Bowen fullname: Bowen, Jo – sequence: 27 givenname: Joanne surname: Brady fullname: Brady, Joanne – sequence: 28 givenname: Robert surname: Brierly fullname: Brierly, Robert – sequence: 29 givenname: Sue surname: Brock fullname: Brock, Sue – sequence: 30 givenname: B surname: Brown Richard fullname: Brown Richard, B – sequence: 31 givenname: Simon surname: Brown fullname: Brown, Simon – sequence: 32 givenname: Michael surname: Button fullname: Button, Michael – sequence: 33 givenname: Philip surname: Camilleri fullname: Camilleri, Philip – sequence: 34 givenname: Lisa surname: Capaldi fullname: Capaldi, Lisa – sequence: 35 givenname: Fiona surname: Castell fullname: Castell, Fiona – sequence: 36 givenname: Eliot surname: Chadwick fullname: Chadwick, Eliot – sequence: 37 givenname: Prabir surname: Chakraborti fullname: Chakraborti, Prabir – sequence: 38 givenname: Andrew surname: Chan fullname: Chan, Andrew – sequence: 39 givenname: Olivia surname: Chan fullname: Chan, Olivia – sequence: 40 givenname: Natalie surname: Charnley fullname: Charnley, Natalie – sequence: 41 givenname: Shan surname: Chetiyawardana fullname: Chetiyawardana, Shan – sequence: 42 givenname: Ananya surname: Choudhurey fullname: Choudhurey, Ananya – sequence: 43 givenname: Ananya surname: Choudhury fullname: Choudhury, Ananya – sequence: 44 givenname: Simon surname: Chowdhury fullname: Chowdhury, Simon – sequence: 45 givenname: Mark surname: Churn fullname: Churn, Mark – sequence: 46 givenname: Amanda surname: Clarke fullname: Clarke, Amanda – sequence: 47 givenname: Noel surname: Clarke fullname: Clarke, Noel – sequence: 48 givenname: J Cole surname: David fullname: David, J Cole – sequence: 49 givenname: Audrey surname: Cook fullname: Cook, Audrey – sequence: 50 givenname: Richard surname: Cowan fullname: Cowan, Richard – sequence: 51 givenname: Simon surname: Crabb fullname: Crabb, Simon – sequence: 52 givenname: Michael surname: Crawford fullname: Crawford, Michael – sequence: 53 givenname: Perric surname: Crellin fullname: Crellin, Perric – sequence: 54 givenname: William surname: Cross fullname: Cross, William – sequence: 55 givenname: Tathagata surname: Das fullname: Das, Tathagata – sequence: 56 givenname: Joe surname: Davies fullname: Davies, Joe – sequence: 57 givenname: Joseph surname: Davies fullname: Davies, Joseph – sequence: 58 givenname: David surname: Dearnaley fullname: Dearnaley, David – sequence: 59 givenname: Jeanette surname: Dickson fullname: Dickson, Jeanette – sequence: 60 givenname: Sajid surname: Durrani fullname: Durrani, Sajid – sequence: 61 givenname: Albert surname: Edwards fullname: Edwards, Albert – sequence: 62 givenname: Andrew surname: Eichholz fullname: Eichholz, Andrew – sequence: 63 givenname: Tony surname: Elliott fullname: Elliott, Tony – sequence: 64 givenname: Chinnamani surname: Eswar fullname: Eswar, Chinnamani – sequence: 65 givenname: Alison surname: Falconer fullname: Falconer, Alison – sequence: 66 givenname: Catherine surname: Ferguson fullname: Ferguson, Catherine – sequence: 67 givenname: Daniel surname: Ford fullname: Ford, Daniel – sequence: 68 givenname: Victoria surname: Ford fullname: Ford, Victoria – sequence: 69 givenname: John surname: Frew fullname: Frew, John – sequence: 70 givenname: Olivera surname: Frim fullname: Frim, Olivera – sequence: 71 givenname: Joanna surname: Gale fullname: Gale, Joanna – sequence: 72 givenname: Stephanie surname: Gibbs fullname: Gibbs, Stephanie – sequence: 73 givenname: Hilary surname: Glen fullname: Glen, Hilary – sequence: 74 givenname: John D surname: Graham fullname: Graham, John D – sequence: 75 givenname: Warren surname: Grant fullname: Grant, Warren – sequence: 76 givenname: Emma surname: Gray fullname: Gray, Emma – sequence: 77 givenname: Teresa surname: Guerrero-Urbano fullname: Guerrero-Urbano, Teresa – sequence: 78 givenname: Nishi surname: Gupta fullname: Gupta, Nishi – sequence: 79 givenname: Abdel surname: Hamid fullname: Hamid, Abdel – sequence: 80 givenname: Joanna surname: Hamilton fullname: Hamilton, Joanna – sequence: 81 givenname: John surname: Hardman fullname: Hardman, John – sequence: 82 givenname: Stephen surname: Harland fullname: Harland, Stephen – sequence: 83 givenname: Peter surname: Harper fullname: Harper, Peter – sequence: 84 givenname: Catherine surname: Heath fullname: Heath, Catherine – sequence: 85 givenname: Ann surname: Henry fullname: Henry, Ann – sequence: 86 givenname: Chris surname: Herbert fullname: Herbert, Chris – sequence: 87 givenname: John surname: Hetherington fullname: Hetherington, John – sequence: 88 givenname: Esme surname: Hill fullname: Hill, Esme – sequence: 89 givenname: Serena surname: Hilman fullname: Hilman, Serena – sequence: 90 givenname: Mohan surname: Hingorani fullname: Hingorani, Mohan – sequence: 91 givenname: Uschi surname: Hofmann fullname: Hofmann, Uschi – sequence: 92 givenname: Peter surname: Hoskin fullname: Hoskin, Peter – sequence: 93 givenname: Robert surname: Huddart fullname: Huddart, Robert – sequence: 94 givenname: Robert surname: Hughes fullname: Hughes, Robert – sequence: 95 givenname: Simon surname: Hughes fullname: Hughes, Simon – sequence: 96 givenname: Azman surname: Ibrahim fullname: Ibrahim, Azman – sequence: 97 givenname: Suneil surname: Jain fullname: Jain, Suneil – sequence: 98 givenname: Sunjay surname: Jain fullname: Jain, Sunjay – sequence: 99 givenname: Nicholas surname: James fullname: James, Nicholas – sequence: 100 givenname: Peter surname: Jenkins fullname: Jenkins, Peter |
| Copyright | 2016 James et al. Open Access article distributed under the terms of CC BY James et al. Open Access article distributed under the terms of CC BY Copyright © 2016 James et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved. Copyright Elsevier Limited Mar 19, 2016 2016 James et al. Open Access article distributed under the terms of CC BY 2016 |
| Copyright_xml | – notice: 2016 James et al. Open Access article distributed under the terms of CC BY – notice: James et al. Open Access article distributed under the terms of CC BY – notice: Copyright © 2016 James et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved. – notice: Copyright Elsevier Limited Mar 19, 2016 – notice: 2016 James et al. Open Access article distributed under the terms of CC BY 2016 |
| CorporateAuthor | STAMPEDE investigators |
| CorporateAuthor_xml | – name: STAMPEDE investigators |
| DBID | 6I. AAFTH AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7QP 7RV 7TK 7U7 7U9 7X7 7XB 88A 88C 88E 88G 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8FK 8G5 ABUWG AEUYN AFKRA AN0 ASE AZQEC BBNVY BEC BENPR BHPHI C1K CCPQU DWQXO FPQ FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K6X K9- K9. KB0 KB~ LK8 M0R M0S M0T M1P M2M M2O M2P M7N M7P MBDVC NAPCQ PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS PSYQQ Q9U S0X 7U8 7X8 JXQ 5PM |
| DOI | 10.1016/S0140-6736(15)01037-5 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Calcium & Calcified Tissue Abstracts Nursing & Allied Health Database Neurosciences Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Biology Database (Alumni Edition) Healthcare Administration Database (Alumni) Medical Database (Alumni Edition) Psychology Database (Alumni) Science Database (Alumni Edition) STEM Database ProQuest Pharma Collection Public Health Database Lancet Titles ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest One Sustainability (subscription) ProQuest Central UK/Ireland British Nursing Database British Nursing Index ProQuest Central Essentials Biological Science Collection (subscription) ProQuest eLibrary (NC LIVE) ProQuest Central Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central British Nursing Index (BNI) (1985 to Present) Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection British Nursing Index Consumer Health Database ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) ProQuest Newsstand Professional Biological Sciences Family Health Database Health & Medical Collection (Alumni Edition) Healthcare Administration Database PML(ProQuest Medical Library) Psychology Database (ProQuest) Research Library Science Database (subscription) Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Research Library (Corporate) Nursing & Allied Health Premium ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China One Psychology ProQuest Central Basic SIRS Editorial TOXLINE MEDLINE - Academic Toxline PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest Central Essentials Lancet Titles elibrary ProQuest AP Science SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Newsstand Professional Virology and AIDS Abstracts ProQuest Science Journals (Alumni Edition) ProQuest Biological Science Collection ProQuest Family Health ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Health Management (Alumni Edition) ProQuest Nursing & Allied Health Source (Alumni) ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest One Academic Middle East (New) SIRS Editorial ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Family Health (Alumni Edition) ProQuest Biology Journals (Alumni Edition) ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Public Health ProQuest Central Basic Toxicology Abstracts ProQuest Science Journals British Nursing Index with Full Text ProQuest Health Management British Nursing Index ProQuest Nursing & Allied Health Source ProQuest Psychology Journals (Alumni) ProQuest SciTech Collection ProQuest Medical Library ProQuest Psychology Journals ProQuest Central (Alumni) TOXLINE MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Psychology TOXLINE MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1474-547X |
| EndPage | 1177 |
| ExternalDocumentID | PMC4800035 3993991361 26719232 10_1016_S0140_6736_15_01037_5 S0140673615010375 1_s2_0_S0140673615010375 |
| Genre | Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation | Cancer Research UK, Medical Research Council, Novartis, Sanofi-Aventis, Pfizer, Janssen, Astellas, NIHR Clinical Research Network, Swiss Group for Clinical Cancer Research. |
| GrantInformation_xml | – fundername: Medical Research Council grantid: MC_UU_12023/25 – fundername: Medical Research Council grantid: MC_UU_12023/20 – fundername: Cancer Research UK grantid: 12459 – fundername: Medical Research Council grantid: MC_UU_12023/28 – fundername: Prostate Cancer UK grantid: PG12-49 – fundername: Cancer Research UK grantid: 10588 – fundername: Cancer Research UK grantid: 12518 – fundername: Cancer Research UK grantid: 19727 – fundername: Cancer Research UK grantid: 3804 – fundername: Cancer Research UK grantid: 13239 |
| GroupedDBID | --- --K --M .1- .55 .CO .FO 0R~ 123 1B1 1P~ 1RT 1~5 29L 4.4 457 4G. 53G 5VS 7-5 71M 7RV 7X7 88E 88I 8AF 8AO 8C1 8C2 8FE 8FH 8FI 8FJ 8G5 9JM AABNK AAEDT AAEDW AAFWJ AAIKJ AAKOC AALRI AAMRU AAQFI AAQQT AATTM AAXKI AAXUO AAYWO ABBQC ABCQX ABFNM ABIVO ABJNI ABLJU ABMAC ABMZM ABOCM ABUFD ABUWG ACGFS ACGOD ACIEU ACIUM ACLOT ACPRK ACRLP ACVFH ADBBV ADCNI AEIPS AEKER AENEX AEUPX AEUYN AEVXI AFKRA AFPUW AFRAH AFRHN AFTJW AFXIZ AGAPS AGHFR AHHHB AHMBA AIIUN AITUG AJRQY AJUYK AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ AN0 ANZVX APXCP AQUVI AXJTR AZQEC BBNVY BCU BEC BENPR BHPHI BKEYQ BKNYI BKOJK BKOMP BNPGV BNQBC BPHCQ BVXVI CCPQU CS3 DU5 DWQXO EAU EBS EFJIC EFKBS EJD EO8 EO9 EP2 EP3 EWM EX3 F5P FD8 FDB FIRID FNPLU FYGXN FYUFA G-2 G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK IHE J1W K-O K9- KOM L7B LK8 LZ2 M0R M0T M1P M2M M2O M2P M7P MJL MO0 N9A NAPCQ O-L O9- OD. OO~ OZT P-8 P-9 P2P PC. PHGZM PHGZT PJZUB PPXIY PQGLB PQQKQ PRG PROAC PSQYO PSYQQ R2- ROL RPZ S0X SAD SDG SEL SES SJFOW SJN SPCBC SSH SSZ T5K TLN TWZ UAP UBE UKHRP UQL UV1 WOW X7M XAX XDU YYM Z5R ZMT ~HD .GJ 04C 3EH 3O- 3V. 41~ 88A 8WZ A6W AACTN AAEJM AAKAS AAQXK AAYOK ABDBF ABTAH ABWVN ACRPL ACRZS ACUHS ADMUD ADNMO ADZCM AFCTW AFFNX AFKWA AHQJS AJJEV AJOXV AKVCP ALIPV AMFUW ARTTT ASPBG AVWKF AZFZN D0S EAP EAS EAZ EBC EBD EBU EGS EHN EIHBH EMB EMK EMOBN ENC EPL EPS EPT ESX EVS FEDTE FGOYB HVGLF HZ~ J5H M0L M41 MVM OVD PKN Q~Q RIG SDF SV3 TEORI TH9 UHU WOQ WUQ XPP YYQ ZGI ZXP ZY4 ~G0 6I. AAFTH ABLVK ABYKQ AHPSJ AJBFU XFK ZA5 9DU AAYXX ADXHL AFFHD AGQPQ AIGII CITATION AGCQF AGRNS CGR CUY CVF ECM EIF NPM 7QL 7QP 7TK 7U7 7U9 7XB 8FK ASE C1K FPQ H94 K6X K9. KB~ M7N MBDVC PKEHL PQEST PQUKI PRINS Q9U 7U8 7X8 JXQ PUEGO 5PM |
| ID | FETCH-LOGICAL-c674t-e52de14fdb5eb62b4cbffab77a3989b93919f1ac714921506ee38035ce8d8b2d3 |
| IEDL.DBID | 7X7 |
| ISICitedReferencesCount | 1579 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000372412000028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 0140-6736 |
| IngestDate | Tue Nov 04 01:56:46 EST 2025 Sun Sep 28 08:43:23 EDT 2025 Sat Nov 29 14:28:36 EST 2025 Mon Jul 21 05:50:49 EDT 2025 Sat Nov 29 05:12:37 EST 2025 Tue Nov 18 22:42:13 EST 2025 Fri Feb 23 02:24:41 EST 2024 Tue Feb 25 20:08:40 EST 2025 Tue Oct 14 19:31:11 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10024 |
| Language | English |
| License | http://creativecommons.org/licenses/by/4.0 Copyright © 2016 James et al. Open Access article distributed under the terms of CC BY. Published by Elsevier Ltd.. All rights reserved. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c674t-e52de14fdb5eb62b4cbffab77a3989b93919f1ac714921506ee38035ce8d8b2d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 ObjectType-Undefined-3 Members listed at end of paper |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC4800035 |
| PMID | 26719232 |
| PQID | 1775104146 |
| PQPubID | 40246 |
| PageCount | 15 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4800035 proquest_miscellaneous_1777485498 proquest_journals_1775104146 pubmed_primary_26719232 crossref_citationtrail_10_1016_S0140_6736_15_01037_5 crossref_primary_10_1016_S0140_6736_15_01037_5 elsevier_sciencedirect_doi_10_1016_S0140_6736_15_01037_5 elsevier_clinicalkeyesjournals_1_s2_0_S0140673615010375 elsevier_clinicalkey_doi_10_1016_S0140_6736_15_01037_5 |
| PublicationCentury | 2000 |
| PublicationDate | 2016-03-19 |
| PublicationDateYYYYMMDD | 2016-03-19 |
| PublicationDate_xml | – month: 03 year: 2016 text: 2016-03-19 day: 19 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | The Lancet (British edition) |
| PublicationTitleAlternate | Lancet |
| PublicationYear | 2016 |
| Publisher | Elsevier Ltd Elsevier Limited Elsevier |
| Publisher_xml | – name: Elsevier Ltd – name: Elsevier Limited – name: Elsevier |
| References | Gravis, Fizazi, Joly (bib26) 2013; 14 James, Spears, Clarke (bib12) 2015; 67 de Bono, Logothetis, Molina (bib3) 2011; 364 Scher, Fizazi, Saad (bib4) 2012; 367 Gravis, Boher, Joly (bib32) 2015; GU Fizazi, Laplanche, Lesaunier (bib33) 2014; 32 Denham, Joseph, Lamb (bib35) 2014; 15 Smith, Egerdie, Hernandez Toriz (bib10) 2009; 361 Smith, Halabi, Ryan (bib37) 2014; 13 Parmar, Barthel, Sydes (bib18) 2008; 100 Saad, Gleason, Murray (bib9) 2004; 96 Cook, Farewell (bib23) 1996; 159 James, Sydes, Clarke (bib19) 2008; 20 Barthel, Royston, Parmar (bib20) 2009; 9 James, Sydes, Mason (bib11) 2012; 13 Vale, Burdett, Rydzewska (bib14) 2015 Sweeney, Chen, Carducci (bib25) 2015; 373 Beer, Armstrong, Rathkopf (bib5) 2014; 371 Wason, Stecher, Mander (bib21) 2014; 15 James, Spears, Clarke (bib13) 2015; 25 Royston, Parmar (bib24) 2002; 21 Omlin, Sartor, Rothermundt (bib28) 2015; 13 Wirth, Tammela, Cicalese (bib36) 2015; 67 Follmann, Proschan, Geller (bib22) 1994; 50 Dearnaley, Mason, Parmar, Sanders, Sydes (bib15) 2009; 10 Aapro, Bohlius, Cameron (bib30) 2011; 47 Parker, Nilsson, Heinrich (bib7) 2013; 369 Kantoff, Higano, Shore (bib8) 2010; 363 de Bono, Oudard, Ozguroglu (bib6) 2010; 376 Sandler, Hu, Rosenthal (bib34) 2015; 33 Tannock, de Wit, Berry (bib2) 2004; 351 Sydes, Parmar, James (bib17) 2009; 10 Franke, Carducci, Rudek, Baker, Sparreboom (bib27) 2010; 28 Smith, Khatcheressian, Lyman (bib29) 2006; 24 Petrylak, Tangen, Hussain (bib1) 2004; 351 Sydes, Parmar, Mason (bib16) 2012; 13 Schweizer, Huang, Kattan (bib31) 2013; 119 Wirth (10.1016/S0140-6736(15)01037-5_bib36) 2015; 67 Parker (10.1016/S0140-6736(15)01037-5_bib7) 2013; 369 Sydes (10.1016/S0140-6736(15)01037-5_bib17) 2009; 10 Schweizer (10.1016/S0140-6736(15)01037-5_bib31) 2013; 119 Smith (10.1016/S0140-6736(15)01037-5_bib10) 2009; 361 Petrylak (10.1016/S0140-6736(15)01037-5_bib1) 2004; 351 James (10.1016/S0140-6736(15)01037-5_bib11) 2012; 13 Smith (10.1016/S0140-6736(15)01037-5_bib29) 2006; 24 Saad (10.1016/S0140-6736(15)01037-5_bib9) 2004; 96 Kantoff (10.1016/S0140-6736(15)01037-5_bib8) 2010; 363 James (10.1016/S0140-6736(15)01037-5_bib12) 2015; 67 Gravis (10.1016/S0140-6736(15)01037-5_bib32) 2015; GU Cook (10.1016/S0140-6736(15)01037-5_bib23) 1996; 159 Beer (10.1016/S0140-6736(15)01037-5_bib5) 2014; 371 Wason (10.1016/S0140-6736(15)01037-5_bib21) 2014; 15 de Bono (10.1016/S0140-6736(15)01037-5_bib3) 2011; 364 Barthel (10.1016/S0140-6736(15)01037-5_bib20) 2009; 9 de Bono (10.1016/S0140-6736(15)01037-5_bib6) 2010; 376 James (10.1016/S0140-6736(15)01037-5_bib13) 2015; 25 Smith (10.1016/S0140-6736(15)01037-5_bib37) 2014; 13 Franke (10.1016/S0140-6736(15)01037-5_bib27) 2010; 28 Omlin (10.1016/S0140-6736(15)01037-5_bib28) 2015; 13 Denham (10.1016/S0140-6736(15)01037-5_bib35) 2014; 15 Dearnaley (10.1016/S0140-6736(15)01037-5_bib15) 2009; 10 Tannock (10.1016/S0140-6736(15)01037-5_bib2) 2004; 351 Sydes (10.1016/S0140-6736(15)01037-5_bib16) 2012; 13 Follmann (10.1016/S0140-6736(15)01037-5_bib22) 1994; 50 Royston (10.1016/S0140-6736(15)01037-5_bib24) 2002; 21 Sweeney (10.1016/S0140-6736(15)01037-5_bib25) 2015; 373 Parmar (10.1016/S0140-6736(15)01037-5_bib18) 2008; 100 Fizazi (10.1016/S0140-6736(15)01037-5_bib33) 2014; 32 James (10.1016/S0140-6736(15)01037-5_bib19) 2008; 20 Aapro (10.1016/S0140-6736(15)01037-5_bib30) 2011; 47 Sandler (10.1016/S0140-6736(15)01037-5_bib34) 2015; 33 Scher (10.1016/S0140-6736(15)01037-5_bib4) 2012; 367 Gravis (10.1016/S0140-6736(15)01037-5_bib26) 2013; 14 Vale (10.1016/S0140-6736(15)01037-5_bib14) 2015 27628795 - J Urol. 2016 Oct;196(4):1124-5. doi: 10.1016/j.juro.2016.07.067. 28786417 - Nat Rev Clin Oncol. 2017 Oct;14(10):592-593. doi: 10.1038/nrclinonc.2017.120. 27236422 - Clin Oncol (R Coll Radiol). 2016 Sep;28(9):547-9. doi: 10.1016/j.clon.2016.04.047. 26787390 - Nat Rev Urol. 2016 Feb;13(2):61. doi: 10.1038/nrurol.2016.4. 27131755 - Clin Oncol (R Coll Radiol). 2016 Sep;28(9):611. doi: 10.1016/j.clon.2016.03.006. 28540244 - Transl Androl Urol. 2017 Apr;6(2):315-316. doi: 10.21037/tau.2017.02.01. 27979458 - Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):6-8. doi: 10.1016/j.ijrobp.2016.06.2453. 28214037 - Actas Urol Esp. 2017 Jul - Aug;41(6):347-351. doi: 10.1016/j.acuro.2016.11.008. 27302137 - Eur Urol. 2016 Jun;69(6):1155-6. doi: 10.1016/j.eururo.2016.02.022. 27025318 - Lancet. 2016 Mar 19;387(10024):1135-7. doi: 10.1016/S0140-6736(15)01235-0. 27479564 - Lancet. 2016 Jul 16;388(10041):234-5. doi: 10.1016/S0140-6736(16)31038-8. 27479566 - Lancet. 2016 Jul 16;388(10041):235-6. doi: 10.1016/S0140-6736(16)31041-8. |
| References_xml | – volume: 10 start-page: 872 year: 2009 end-page: 876 ident: bib15 article-title: Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials publication-title: Lancet Oncol – volume: 13 start-page: 27 year: 2014 ident: bib37 article-title: Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance) publication-title: J Clin Oncol – volume: 364 start-page: 1995 year: 2011 end-page: 2005 ident: bib3 article-title: Abiraterone and increased survival in metastatic prostate cancer publication-title: N Engl J Med – volume: 67 start-page: 482 year: 2015 end-page: 491 ident: bib36 article-title: Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS) publication-title: Eur Urol – volume: 33 start-page: LBA52022 year: 2015 ident: bib34 article-title: A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with doxetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521) publication-title: Proc Am Soc Clin Oncol – volume: 367 start-page: 1187 year: 2012 end-page: 1197 ident: bib4 article-title: Increased survival with enzalutamide in prostate cancer after chemotherapy publication-title: N Engl J Med – volume: 28 start-page: 4562 year: 2010 end-page: 4567 ident: bib27 article-title: Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer publication-title: J Clin Oncol – volume: 13 start-page: e205 year: 2015 end-page: e208 ident: bib28 article-title: Analysis of side effect profile of alopecia, nail changes, peripheral neuropathy, and dysgeusia in prostate cancer patients treated with docetaxel and cabazitaxel publication-title: Clin Genitourin Cancer – year: 2015 ident: bib14 article-title: Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data publication-title: Lancet Oncol – volume: 100 start-page: 1204 year: 2008 end-page: 1214 ident: bib18 article-title: Speeding up the evaluation of new agents in cancer publication-title: J Natl Cancer Inst – volume: 351 start-page: 1502 year: 2004 end-page: 1512 ident: bib2 article-title: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer publication-title: N Engl J Med – volume: 361 start-page: 745 year: 2009 end-page: 755 ident: bib10 article-title: Denosumab in men receiving androgen-deprivation therapy for prostate cancer publication-title: N Engl J Med – volume: 10 start-page: 39 year: 2009 ident: bib17 article-title: Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial publication-title: Trials – volume: 363 start-page: 411 year: 2010 end-page: 422 ident: bib8 article-title: Sipuleucel-T immunotherapy for castration-resistant prostate cancer publication-title: N Engl J Med – volume: 13 start-page: 549 year: 2012 end-page: 558 ident: bib11 article-title: Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial publication-title: Lancet Oncol – volume: 21 start-page: 2175 year: 2002 end-page: 2197 ident: bib24 article-title: Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects publication-title: Stat Med – volume: 376 start-page: 1147 year: 2010 end-page: 1154 ident: bib6 article-title: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial publication-title: Lancet – volume: GU start-page: 140 year: 2015 ident: bib32 article-title: Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (Pca): long-term analysis of the GETUG-AFU-15 phase III trial publication-title: Proc Am Soc Clin Oncol – volume: 32 start-page: A5005 year: 2014 ident: bib33 article-title: Docetaxel–estramustine in localized high-risk prostate cancer: results of the French Genitourinary Tumor Group GETUG 12 phase III trial publication-title: Proc Am Soc Clin Oncol – volume: 24 start-page: 3187 year: 2006 end-page: 3205 ident: bib29 article-title: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline publication-title: J Clin Oncol – volume: 67 start-page: 1028 year: 2015 end-page: 1038 ident: bib12 article-title: Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019) publication-title: Eur Urol – volume: 9 start-page: 505 year: 2009 ident: bib20 article-title: A menu-driven facility for sample-size calculation in novel multiarm, multistage randomized controlled trials with a time-to-event outcome publication-title: Stata J – volume: 351 start-page: 1513 year: 2004 end-page: 1520 ident: bib1 article-title: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer publication-title: N Engl J Med – volume: 47 start-page: 8 year: 2011 end-page: 32 ident: bib30 article-title: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours publication-title: Eur J Cancer – volume: 369 start-page: 213 year: 2013 end-page: 223 ident: bib7 article-title: Alpha emitter radium-223 and survival in metastatic prostate cancer publication-title: N Engl J Med – volume: 119 start-page: 3610 year: 2013 end-page: 3618 ident: bib31 article-title: Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials publication-title: Cancer – volume: 373 start-page: 737 year: 2015 end-page: 746 ident: bib25 article-title: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer publication-title: N Engl J Med – volume: 371 start-page: 424 year: 2014 end-page: 433 ident: bib5 article-title: Enzalutamide in metastatic prostate cancer before chemotherapy publication-title: N Engl J Med – volume: 96 start-page: 879 year: 2004 end-page: 882 ident: bib9 article-title: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer publication-title: J Natl Cancer Inst – volume: 14 start-page: 149 year: 2013 end-page: 158 ident: bib26 article-title: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial publication-title: Lancet Oncol – volume: 25 start-page: 1 year: 2015 end-page: 10 ident: bib13 article-title: Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial publication-title: JAMA Oncol – volume: 50 start-page: 325 year: 1994 end-page: 336 ident: bib22 article-title: Monitoring pairwise comparisons in multi-armed clinical trials publication-title: Biometrics – volume: 13 start-page: 168 year: 2012 ident: bib16 article-title: Flexible trial design in practice-stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial publication-title: Trials – volume: 20 start-page: 577 year: 2008 end-page: 581 ident: bib19 article-title: STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer—a multi-arm multi-stage randomised controlled trial publication-title: Clin Oncol – volume: 15 start-page: 364 year: 2014 ident: bib21 article-title: Correcting for multiple-testing in multi-arm trials: is it necessary and is it done? publication-title: Trials – volume: 159 start-page: 93 year: 1996 end-page: 110 ident: bib23 article-title: Multiplicity considerations in the design and analysis of clinical trials publication-title: J R Stat Soc Series A – volume: 15 start-page: 1076 year: 2014 end-page: 1089 ident: bib35 article-title: Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial publication-title: Lancet Oncol – volume: 15 start-page: 364 year: 2014 ident: 10.1016/S0140-6736(15)01037-5_bib21 article-title: Correcting for multiple-testing in multi-arm trials: is it necessary and is it done? publication-title: Trials doi: 10.1186/1745-6215-15-364 – volume: 33 start-page: LBA52022 issue: suppl year: 2015 ident: 10.1016/S0140-6736(15)01037-5_bib34 article-title: A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with doxetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521) publication-title: Proc Am Soc Clin Oncol – volume: 96 start-page: 879 year: 2004 ident: 10.1016/S0140-6736(15)01037-5_bib9 article-title: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djh141 – volume: 351 start-page: 1502 year: 2004 ident: 10.1016/S0140-6736(15)01037-5_bib2 article-title: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa040720 – volume: 20 start-page: 577 year: 2008 ident: 10.1016/S0140-6736(15)01037-5_bib19 article-title: STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer—a multi-arm multi-stage randomised controlled trial publication-title: Clin Oncol doi: 10.1016/j.clon.2008.07.002 – volume: 363 start-page: 411 year: 2010 ident: 10.1016/S0140-6736(15)01037-5_bib8 article-title: Sipuleucel-T immunotherapy for castration-resistant prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1001294 – volume: 13 start-page: 549 year: 2012 ident: 10.1016/S0140-6736(15)01037-5_bib11 article-title: Celecoxib plus hormone therapy versus hormone therapy alone for hormone-sensitive prostate cancer: first results from the STAMPEDE multiarm, multistage, randomised controlled trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70088-8 – volume: 67 start-page: 1028 year: 2015 ident: 10.1016/S0140-6736(15)01037-5_bib12 article-title: Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019) publication-title: Eur Urol doi: 10.1016/j.eururo.2014.09.032 – volume: 364 start-page: 1995 year: 2011 ident: 10.1016/S0140-6736(15)01037-5_bib3 article-title: Abiraterone and increased survival in metastatic prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1014618 – volume: 119 start-page: 3610 year: 2013 ident: 10.1016/S0140-6736(15)01037-5_bib31 article-title: Adjuvant leuprolide with or without docetaxel in patients with high-risk prostate cancer after radical prostatectomy (TAX-3501): important lessons for future trials publication-title: Cancer doi: 10.1002/cncr.28270 – volume: 28 start-page: 4562 year: 2010 ident: 10.1016/S0140-6736(15)01037-5_bib27 article-title: Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer publication-title: J Clin Oncol doi: 10.1200/JCO.2010.30.7025 – volume: 13 start-page: e205 year: 2015 ident: 10.1016/S0140-6736(15)01037-5_bib28 article-title: Analysis of side effect profile of alopecia, nail changes, peripheral neuropathy, and dysgeusia in prostate cancer patients treated with docetaxel and cabazitaxel publication-title: Clin Genitourin Cancer doi: 10.1016/j.clgc.2015.01.010 – volume: 24 start-page: 3187 year: 2006 ident: 10.1016/S0140-6736(15)01037-5_bib29 article-title: 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline publication-title: J Clin Oncol doi: 10.1200/JCO.2006.06.4451 – volume: 369 start-page: 213 year: 2013 ident: 10.1016/S0140-6736(15)01037-5_bib7 article-title: Alpha emitter radium-223 and survival in metastatic prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1213755 – volume: 13 start-page: 168 year: 2012 ident: 10.1016/S0140-6736(15)01037-5_bib16 article-title: Flexible trial design in practice-stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial publication-title: Trials doi: 10.1186/1745-6215-13-168 – volume: 25 start-page: 1 year: 2015 ident: 10.1016/S0140-6736(15)01037-5_bib13 article-title: Failure-free survival and radiotherapy in patients with newly diagnosed nonmetastatic prostate cancer: data from patients in the control arm of the STAMPEDE trial publication-title: JAMA Oncol – volume: 21 start-page: 2175 year: 2002 ident: 10.1016/S0140-6736(15)01037-5_bib24 article-title: Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects publication-title: Stat Med doi: 10.1002/sim.1203 – volume: 50 start-page: 325 year: 1994 ident: 10.1016/S0140-6736(15)01037-5_bib22 article-title: Monitoring pairwise comparisons in multi-armed clinical trials publication-title: Biometrics doi: 10.2307/2533376 – volume: 47 start-page: 8 year: 2011 ident: 10.1016/S0140-6736(15)01037-5_bib30 article-title: 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours publication-title: Eur J Cancer doi: 10.1016/j.ejca.2010.10.013 – volume: 13 start-page: 27 year: 2014 ident: 10.1016/S0140-6736(15)01037-5_bib37 article-title: Efficacy and safety of zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance) publication-title: J Clin Oncol – volume: 371 start-page: 424 year: 2014 ident: 10.1016/S0140-6736(15)01037-5_bib5 article-title: Enzalutamide in metastatic prostate cancer before chemotherapy publication-title: N Engl J Med doi: 10.1056/NEJMoa1405095 – volume: 67 start-page: 482 year: 2015 ident: 10.1016/S0140-6736(15)01037-5_bib36 article-title: Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS) publication-title: Eur Urol doi: 10.1016/j.eururo.2014.02.014 – volume: 367 start-page: 1187 year: 2012 ident: 10.1016/S0140-6736(15)01037-5_bib4 article-title: Increased survival with enzalutamide in prostate cancer after chemotherapy publication-title: N Engl J Med doi: 10.1056/NEJMoa1207506 – volume: 159 start-page: 93 year: 1996 ident: 10.1016/S0140-6736(15)01037-5_bib23 article-title: Multiplicity considerations in the design and analysis of clinical trials publication-title: J R Stat Soc Series A doi: 10.2307/2983471 – volume: 351 start-page: 1513 year: 2004 ident: 10.1016/S0140-6736(15)01037-5_bib1 article-title: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa041318 – volume: 10 start-page: 872 year: 2009 ident: 10.1016/S0140-6736(15)01037-5_bib15 article-title: Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials publication-title: Lancet Oncol doi: 10.1016/S1470-2045(09)70201-3 – volume: 10 start-page: 39 year: 2009 ident: 10.1016/S0140-6736(15)01037-5_bib17 article-title: Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial publication-title: Trials doi: 10.1186/1745-6215-10-39 – volume: GU start-page: 140 issue: suppl year: 2015 ident: 10.1016/S0140-6736(15)01037-5_bib32 article-title: Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-naïve metastatic prostate cancer (Pca): long-term analysis of the GETUG-AFU-15 phase III trial publication-title: Proc Am Soc Clin Oncol doi: 10.1200/jco.2015.33.7_suppl.140 – year: 2015 ident: 10.1016/S0140-6736(15)01037-5_bib14 article-title: Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data publication-title: Lancet Oncol – volume: 376 start-page: 1147 year: 2010 ident: 10.1016/S0140-6736(15)01037-5_bib6 article-title: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial publication-title: Lancet doi: 10.1016/S0140-6736(10)61389-X – volume: 15 start-page: 1076 year: 2014 ident: 10.1016/S0140-6736(15)01037-5_bib35 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(14)70328-6 – volume: 100 start-page: 1204 year: 2008 ident: 10.1016/S0140-6736(15)01037-5_bib18 article-title: Speeding up the evaluation of new agents in cancer publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djn267 – volume: 14 start-page: 149 year: 2013 ident: 10.1016/S0140-6736(15)01037-5_bib26 article-title: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial publication-title: Lancet Oncol doi: 10.1016/S1470-2045(12)70560-0 – volume: 373 start-page: 737 year: 2015 ident: 10.1016/S0140-6736(15)01037-5_bib25 article-title: Chemohormonal therapy in metastatic hormone-sensitive prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa1503747 – volume: 32 start-page: A5005 issue: suppl year: 2014 ident: 10.1016/S0140-6736(15)01037-5_bib33 article-title: Docetaxel–estramustine in localized high-risk prostate cancer: results of the French Genitourinary Tumor Group GETUG 12 phase III trial publication-title: Proc Am Soc Clin Oncol doi: 10.1200/jco.2014.32.15_suppl.5005 – volume: 361 start-page: 745 year: 2009 ident: 10.1016/S0140-6736(15)01037-5_bib10 article-title: Denosumab in men receiving androgen-deprivation therapy for prostate cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa0809003 – volume: 9 start-page: 505 year: 2009 ident: 10.1016/S0140-6736(15)01037-5_bib20 article-title: A menu-driven facility for sample-size calculation in novel multiarm, multistage randomized controlled trials with a time-to-event outcome publication-title: Stata J doi: 10.1177/1536867X0900900401 – reference: 27236422 - Clin Oncol (R Coll Radiol). 2016 Sep;28(9):547-9. doi: 10.1016/j.clon.2016.04.047. – reference: 27628795 - J Urol. 2016 Oct;196(4):1124-5. doi: 10.1016/j.juro.2016.07.067. – reference: 28214037 - Actas Urol Esp. 2017 Jul - Aug;41(6):347-351. doi: 10.1016/j.acuro.2016.11.008. – reference: 27302137 - Eur Urol. 2016 Jun;69(6):1155-6. doi: 10.1016/j.eururo.2016.02.022. – reference: 26787390 - Nat Rev Urol. 2016 Feb;13(2):61. doi: 10.1038/nrurol.2016.4. – reference: 28786417 - Nat Rev Clin Oncol. 2017 Oct;14(10):592-593. doi: 10.1038/nrclinonc.2017.120. – reference: 27025318 - Lancet. 2016 Mar 19;387(10024):1135-7. doi: 10.1016/S0140-6736(15)01235-0. – reference: 27479564 - Lancet. 2016 Jul 16;388(10041):234-5. doi: 10.1016/S0140-6736(16)31038-8. – reference: 27979458 - Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):6-8. doi: 10.1016/j.ijrobp.2016.06.2453. – reference: 28540244 - Transl Androl Urol. 2017 Apr;6(2):315-316. doi: 10.21037/tau.2017.02.01. – reference: 27131755 - Clin Oncol (R Coll Radiol). 2016 Sep;28(9):611. doi: 10.1016/j.clon.2016.03.006. – reference: 27479566 - Lancet. 2016 Jul 16;388(10041):235-6. doi: 10.1016/S0140-6736(16)31041-8. |
| SSID | ssj0004605 |
| Score | 2.6873574 |
| Snippet | Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using a... Summary Background Long-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled... BACKGROUNDLong-term hormone therapy has been the standard of care for advanced prostate cancer since the 1940s. STAMPEDE is a randomised controlled trial using... |
| SourceID | pubmedcentral proquest pubmed crossref elsevier |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1163 |
| SubjectTerms | Adult Aged Aged, 80 and over Androgen Antagonists - administration & dosage Androgen Antagonists - adverse effects Antineoplastic Agents, Hormonal - administration & dosage Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cancer therapies Clinical trials Diphosphonates - administration & dosage Diphosphonates - adverse effects Disease Progression Docetaxel Drug Administration Schedule Heterogeneity Hormone replacement therapy Humans Imidazoles - administration & dosage Imidazoles - adverse effects Internal Medicine Kaplan-Meier Estimate Male Medical prognosis Medical research Metastasis Middle Aged Neoplasm Metastasis Prostate cancer Prostatic Neoplasms - drug therapy Statistical analysis Survival Survival analysis Taxoids - administration & dosage Taxoids - adverse effects Treatment Outcome Zoledronic Acid |
| Title | Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial |
| URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0140673615010375 https://www.clinicalkey.es/playcontent/1-s2.0-S0140673615010375 https://dx.doi.org/10.1016/S0140-6736(15)01037-5 https://www.ncbi.nlm.nih.gov/pubmed/26719232 https://www.proquest.com/docview/1775104146 https://www.proquest.com/docview/1777485498 https://pubmed.ncbi.nlm.nih.gov/PMC4800035 |
| Volume | 387 |
| WOSCitedRecordID | wos000372412000028&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVPQU databaseName: Biological Science Database customDbUrl: eissn: 1474-547X dateEnd: 20250914 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M7P dateStart: 19920104 isFulltext: true titleUrlDefault: http://search.proquest.com/biologicalscijournals providerName: ProQuest – providerCode: PRVPQU databaseName: Consumer Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250914 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0R dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/familyhealth providerName: ProQuest – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1474-547X dateEnd: 20250914 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7X7 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: Healthcare Administration Database customDbUrl: eissn: 1474-547X dateEnd: 20250914 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M0T dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/healthmanagement providerName: ProQuest – providerCode: PRVPQU databaseName: Nursing & Allied Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250914 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 7RV dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/nahs providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 1474-547X dateEnd: 20250914 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: BENPR dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Research Library customDbUrl: eissn: 1474-547X dateEnd: 20250914 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2O dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/pqrl providerName: ProQuest – providerCode: PRVPQU databaseName: Psychology Database (ProQuest) customDbUrl: eissn: 1474-547X dateEnd: 20250914 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2M dateStart: 19920104 isFulltext: true titleUrlDefault: https://www.proquest.com/psychology providerName: ProQuest – providerCode: PRVPQU databaseName: Public Health Database customDbUrl: eissn: 1474-547X dateEnd: 20250914 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: 8C1 dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/publichealth providerName: ProQuest – providerCode: PRVPQU databaseName: Science Database (subscription) customDbUrl: eissn: 1474-547X dateEnd: 20250914 omitProxy: false ssIdentifier: ssj0004605 issn: 0140-6736 databaseCode: M2P dateStart: 19920104 isFulltext: true titleUrlDefault: https://search.proquest.com/sciencejournals providerName: ProQuest |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bb9MwFLZgQ4gX7pfCqA4SD5u0sDpxapsXVEYnHmiptjLtLbJjZ6tUktK0CPid_CCOnTRjUBgSL0etk5PEyefjL_G5EPKcCqtkmImAKcoCpo0KJDYEaZRpqa3h1pfpPH7Hh0NxciJH9Qe3snarXNlEb6hNkbpv5HuUc4QPw4H9avYpcFWj3OpqXULjKtl0ZbMdzvkJXxcX6V3czyN49o6axm0a73R8tFz8p7npd-75qwvlT3PSwa3_7c1tcrNmo9Cr4HOHXLH5XXJ9UK-33yPfe8Z4ny4oMsCj2oX6Yqe78K2YWuOz6oJKJ2YXijlofOawKCCbIKEMHHuFaZGfBs72wxlS4wJbqnCvrzDJYebiTZDpQuqAN4fto3FvMOq_6e-8hHKJFgzHAMxtuZwuSnBRMKByUEbNnIHeBe8JqeYf6194qFNsnU3VwtFwwCnYFIhha6D2xscrBl-j5D75cNAf778N6joQQdrlbBHYODSWsszo2OpuqFmqs0xpzlUkhdQyklRmVKUc3_ZClzHR2kh0oji1wggdmugB2cixj48IRKZDFUcWpLhmSmpFw5SbKFUsliy2rEXYCgFJWidJd7U6pskabzgaJx44SdwiLxq1WZUl5DKF7gpeySoEFo12gvPYZYp8naIta9NTJjQpw6RTaTtlvCFOFTVFo1mzq4o1_ctJt1YoTs7P00C4RZ41m_HBuhUnldti6ffhTMRMihZ5WA2Y5v6EXe7eLkLs0YWh1OzgEp9f3JJPznwCdCb8Cvjjv1_WE3ID2W3XOQxSuUU2FvOlfUqupZ8Rk_M2WorD47a3F14KlGKftsnm6_5wdIj_Bp1Kjp0MB16-93LkJB_9ANjyelg |
| linkProvider | ProQuest |
| linkToHtml | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGQMAL90thwEECaZMWVidOHSMhVO2iTWurSdvQ3oIdO1ulkpSmBcaP4tfwgzh2LmMwGC974C1ycpLYOZ_P5_hcCHlBIyOFn0Yek5R5TGnpCWzwkiBVQhnNjSvT-a7HB4Po4EDszJFvdSyMdaus50Q3Ues8sf_IVyjnqD4Mgf12_NGzVaPs7mpdQqNUi21z_BmXbMWbrTX8vi99f2N9b3XTq6oKeEmHs6lnQl8bylKtQqM6vmKJSlOpOJeBiIQSgaAipTLhuHbwbf49Y4KoHYSJiXSkfB3gfS-RyyzwA4uiaJWeFYfpXOpPIoZWdpvGRRoutV10XvgnW_g71_3VZfMnG7hx838bvVvkRsW2oVvC4zaZM9kdcrVf-RPcJd-7WjufNchTwF6YqfxiRsvwNR8Z7bIGg0yGehnyCSjUaZjmkA6RMHuWncMozw49a9vgCKl_ji1lONsxDDMY23gaZPKQWGBNYHF3r9vfWV9bX3oNxQxnaMQ4TEwxG00LsFE-IDOQWo6tAVoG5-kpJx-qI7zVIbaOR3JqlxmAFEPniFGjoYo2wDcGV4PlHtm_kDG9T-Yz7ONDAoFuU8mR5UmumBRKUj_hOkgkCwULDWsRVmtcnFRJ4G0tklF8hrcfDWOnqHHYIq8asXGZBeU8gU6tznEd4otGKUY7fZ4gP0vQFNXUWsQ0Lvy4XUpbYRwQK4qSUSNZsceSFf7LQxdq1MQnz2kg0yLPm9P4Ye2OmsxMPnPXcBaFTEQt8qAEaDM-fofb1ZOPPToF3eYCm9j99JlseOQSvLPI7fA_-vtrPSPXNvf6vbi3Ndh-TK4jk-9Y50gqFsj8dDIzT8iV5BPq5-Spm6WAvL9oYP8Aam_OrA |
| linkToPdf | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1bb9MwFLbGhiZeuF8KAw4SSJvUsCZx6hgJoUJbMW2rKjbQ3oIdO1ulkpQkBcZP43fwgzjObQwK42UPvFWOTxI75_Kd-lwIeWz7WnAn8i0qbGpRqYTFccAK3UhyqRXTRZvOdztsNPIPDvh4iXyrc2FMWGWtEwtFrZLQ_Ee-aTOG7ENNg5aoCosY94cvZh8t00HKnLTW7TRKFtnWx5_Rfcueb_XxWz9xnOFg_9Vrq-owYIVdRnNLe47SNo2U9LTsOpKGMoqEZEy43OeSu9zmkS1Chn6EY2rxae36HdcLta986SgX73uBrDCch47fysvBaPxmUVZmEWB_kj-0udcMrtveRqfI1fP-ZBl_R76_BnD-ZBGHV_7nvbxKLlc4HHql4FwjSzq-TlZ3q0iDG-R7T6kimg2SCHBFOhdf9LQNX5OpVkU9YRDhRLUhSUEit0OeQDRBKG0Z3A7TJD60jNWDI3QKEhwpE92OYRLDzGTaIMaH0IhcCut7-73d8aA_2HgG2Rx1N0o_pDqbT_MMTP4PiBiEEjNjmtpQxICK9EP1C291iKOzqciNAwIIPlSC0qsVVHkI-MZQdGe5Sd6ey57eIssxrvEOAVd1bMEQ_wkmqeBS2E7IlBsK6nHqadoitOa-IKzKw5suJdNgQRyg7QUF0wZeizxtyGZlfZSzCLo1awd18i-aqwAt-FmEbBGhziqlmwV2kDlBp6Q2xLghhhQp_YaywpUlXvyXh67VEhScPKcRnxZ51FzGD2vO2kSsk3kxh1Hfo9xvkdulsDb743SZ8ascXNEpMW4mmJLvp6_Ek6Oi9Dv1i7P_u39_rYdkFeU52Nkabd8jlxDid03UpM3XyHKezvV9cjH8hOyZPqhUFpD35y3ZPwCgJdkK |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Addition+of+docetaxel%2C+zoledronic+acid%2C+or+both+to+first-line+long-term+hormone+therapy+in+prostate+cancer+%28STAMPEDE%29%3A+survival+results+from+an+adaptive%2C+multiarm%2C+multistage%2C+platform+randomised+controlled+trial&rft.jtitle=The+Lancet+%28British+edition%29&rft.au=James%2C+Nicholas+D&rft.au=Sydes%2C+Matthew+R&rft.au=Clarke%2C+Noel+W&rft.au=Mason%2C+Malcolm+D&rft.date=2016-03-19&rft.pub=Elsevier+Ltd&rft.issn=0140-6736&rft.eissn=1474-547X&rft.volume=387&rft.issue=10024&rft.spage=1163&rft.epage=1177&rft_id=info:doi/10.1016%2FS0140-6736%2815%2901037-5&rft.externalDocID=S0140673615010375 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0140-6736&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0140-6736&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0140-6736&client=summon |